STOCK TITAN

Positron posts $972K Q3 loss, going-concern warning

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Positron Corporation reported third-quarter 2026 sales of $102,667 and a net loss of $971,982. For the first nine months, sales were $325,489 and net loss was $3.17 million, compared with $350,452 and $3.70 million a year earlier. Nine-month gross loss widened to $1.18 million from $796,174. All recognized revenue came from maintenance services; no equipment-sale revenue was recognized.

At September 30, 2026, cash was $1.93 million, total liabilities were $4.21 million and stockholders' deficit was $550,223. Operating activities used $2.42 million in the first nine months. Positron says it does not expect revenue and positive operating cash flows to cover current obligations and reports substantial doubt about its ability to continue as a going concern within the 12 months following issuance of the statements.

It issued $1.9 million of related-party notes due September 30, 2027, bearing 20% annual interest, and had a separate $2 million related-party line of credit with no advances drawn at period-end. Delivery of an equipment system to a customer depends on completion of installment payments under the sale agreement and FDA clearance, which remained subject to regulatory review.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 2 points

How the balance works

Positive

  • Moderate pointNine-month net loss narrowed to $3.17 million from $3.70 million.

Negative

  • Major pointGoing-concern substantial doubt extends through the 12 months after issuance.
  • Moderate pointNine-month sales declined to $325,489 from $350,452.

Filing Explained

At quarter-end, 7.68 million options and warrants represented potential shares, not shares already issued.

During the quarter, Positron issued 250,000 common shares upon warrant exercise and granted 680,000 new warrants with related-party financing; if exercised, the new warrants could add shares and reduce existing holders’ percentage ownership, absent offsetting changes.

The warrants issued with $1,900,000 of notes have a $2-per-share exercise price; the separate 300,000 warrants for the $2,000,000 revolving line have a $1.50 exercise price. At quarter-end, no advances had been drawn on the line, but its warrants remain outstanding whether or not borrowing occurs.

At September 30, 2026, the filing listed 2.53 million warrants and 5.15 million options, 7.68 million potential common shares in total; it excluded them from diluted loss per share because their inclusion would have been anti-dilutive.

Nine-month sales $325,489 Nine months ended September 30, 2026; $350,452 in 2025.
Nine-month net loss $3,171,151 loss Nine months ended September 30, 2026; $3,702,063 loss in 2025.
Nine-month gross loss $1,181,170 loss Nine months ended September 30, 2026; $796,174 loss in 2025.
Cash and cash equivalents $1,925,653 As of September 30, 2026.
Net cash used in operating activities $2,419,813 Nine months ended September 30, 2026; compared with $3,363,257 used in 2025.
Related-party notes issued $1,900,000 principal Issued September 30, 2026; 20% annual interest; matures September 30, 2027.
Related-party line of credit $2,000,000 At September 30, 2026, no advances had been drawn.
Common shares outstanding 33,096,326 shares As of November 13, 2026.
substantial doubt financial
"substantial doubt about the Company’s ability to continue as a going concern"
deferred revenue financial
"consideration received from customers prior to satisfaction of the related performance obligation"
Cash a company has already received for goods or services it has promised but not yet delivered; it's recorded as a liability because the company still owes that product, service, or future revenue recognition. For investors, deferred revenue signals upcoming work or deliveries that will convert into reported sales over time and affects short-term obligations, cash flow quality, and how quickly a firm can grow recognized revenue—think of it like prepaid subscriptions or gift cards a business must honor later.
performance obligation financial
"single stand-ready performance obligation"
A performance obligation is a specific promise in a contract to deliver a good or provide a service to a customer, and it is the unit companies use to decide when and how much revenue to record. Think of it like checklist items in a service agreement: each item completed can trigger part of the payment to be recognized as revenue. Investors care because how obligations are identified and satisfied changes the timing and amount of reported revenue and profits, affecting comparisons and valuation.
510(k) amendment regulatory
"preparation for submission of a 510(k) amendment"
net realizable value financial
"lower of cost or net realizable value"
Net realizable value is the estimated amount a company expects to receive from selling an asset—typically inventory or a receivable—after subtracting any costs needed to finish, sell, or collect it. For investors it shows whether assets on the balance sheet are likely to convert into cash at their stated value, much like estimating how much you’d actually get from a garage sale after cleaning and listing fees; large gaps can signal future write-downs or weaker earnings.
debt discount financial
"resulting in a debt discount of $412,429"
The shortfall between a debt instrument’s face (par) value and the lower price at which it is sold or traded. When debt is issued or traded at a discount, the buyer pays less than the amount that will be repaid at maturity; that discount implies a higher effective yield to the buyer than the stated coupon and, for accounting, is amortized over the life of the debt (or recorded as a loss if the discount reflects a negotiated reduction in repayment).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were POSC's sales and net loss in the third quarter of 2026?

POSC reported sales of $102,667 and a net loss of $971,982 for the three months ended September 30, 2026. In the same quarter of 2025, sales were $111,000 and net loss was $1,043,940.

What are the terms of Positron's $2 million line of credit?

The related-party line of credit matures August 13, 2028. Advances bear interest at 12% per annum, payable quarterly in arrears, with principal payable from August 13, 2027 through maturity. The line is unsecured, and advances may be prepaid without penalty and reborrowed.

How much of POSC's revenue came from its largest customers?

For the nine months ended September 30, 2026, each of five customers represented at least 10% of revenue, and together they accounted for 99.75%. Their individual shares were 23.04%, 21.66%, 20.74%, 20.48% and 13.83%.

When can Positron recognize revenue from its equipment sale?

Equipment-sale revenue is recognized upon physical delivery and acceptance when collection is probable. For the pending system sale, delivery depends on completion of installment payments under the executed agreement and FDA clearance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false Q3 2026 --12-31 0000844985 3171151 2419813 148108230 550223 2025-07-08 2030-07-08 2022-06-01 2027-05-31 0000844985 2026-01-01 2026-09-30 0000844985 2026-11-13 0000844985 2026-09-30 0000844985 2025-12-31 0000844985 2026-07-01 2026-09-30 0000844985 2025-07-01 2025-09-30 0000844985 2025-01-01 2025-09-30 0000844985 posc:SeriesAPreferredStocksMember 2025-12-31 0000844985 posc:SeriesBPreferredStocksMember 2025-12-31 0000844985 us-gaap:PreferredStockMember 2025-12-31 0000844985 us-gaap:CommonStockMember 2025-12-31 0000844985 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0000844985 us-gaap:RetainedEarningsMember 2025-12-31 0000844985 us-gaap:TreasuryStockCommonMember 2025-12-31 0000844985 posc:SeriesAPreferredStocksMember 2026-03-31 0000844985 posc:SeriesBPreferredStocksMember 2026-03-31 0000844985 us-gaap:PreferredStockMember 2026-03-31 0000844985 us-gaap:CommonStockMember 2026-03-31 0000844985 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0000844985 us-gaap:RetainedEarningsMember 2026-03-31 0000844985 us-gaap:TreasuryStockCommonMember 2026-03-31 0000844985 2026-03-31 0000844985 posc:SeriesAPreferredStocksMember 2026-06-30 0000844985 posc:SeriesBPreferredStocksMember 2026-06-30 0000844985 us-gaap:PreferredStockMember 2026-06-30 0000844985 us-gaap:CommonStockMember 2026-06-30 0000844985 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0000844985 us-gaap:RetainedEarningsMember 2026-06-30 0000844985 us-gaap:TreasuryStockCommonMember 2026-06-30 0000844985 2026-06-30 0000844985 posc:SeriesAPreferredStocksMember 2024-12-31 0000844985 posc:SeriesBPreferredStocksMember 2024-12-31 0000844985 us-gaap:CommonStockMember 2024-12-31 0000844985 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000844985 us-gaap:RetainedEarningsMember 2024-12-31 0000844985 us-gaap:TreasuryStockCommonMember 2024-12-31 0000844985 2024-12-31 0000844985 posc:SeriesAPreferredStocksMember 2025-03-31 0000844985 posc:SeriesBPreferredStocksMember 2025-03-31 0000844985 us-gaap:CommonStockMember 2025-03-31 0000844985 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000844985 us-gaap:RetainedEarningsMember 2025-03-31 0000844985 us-gaap:TreasuryStockCommonMember 2025-03-31 0000844985 2025-03-31 0000844985 posc:SeriesAPreferredStocksMember 2025-06-30 0000844985 posc:SeriesBPreferredStocksMember 2025-06-30 0000844985 us-gaap:CommonStockMember 2025-06-30 0000844985 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0000844985 us-gaap:RetainedEarningsMember 2025-06-30 0000844985 us-gaap:TreasuryStockCommonMember 2025-06-30 0000844985 2025-06-30 0000844985 posc:SeriesAPreferredStocksMember 2026-01-01 2026-03-31 0000844985 posc:SeriesBPreferredStocksMember 2026-01-01 2026-03-31 0000844985 us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0000844985 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0000844985 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0000844985 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0000844985 us-gaap:TreasuryStockCommonMember 2026-01-01 2026-03-31 0000844985 2026-01-01 2026-03-31 0000844985 posc:SeriesAPreferredStocksMember 2026-04-01 2026-06-30 0000844985 posc:SeriesBPreferredStocksMember 2026-04-01 2026-06-30 0000844985 us-gaap:PreferredStockMember 2026-04-01 2026-06-30 0000844985 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0000844985 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0000844985 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0000844985 us-gaap:TreasuryStockCommonMember 2026-04-01 2026-06-30 0000844985 2026-04-01 2026-06-30 0000844985 posc:SeriesAPreferredStocksMember 2026-07-01 2026-09-30 0000844985 posc:SeriesBPreferredStocksMember 2026-07-01 2026-09-30 0000844985 us-gaap:PreferredStockMember 2026-07-01 2026-09-30 0000844985 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0000844985 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0000844985 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0000844985 us-gaap:TreasuryStockCommonMember 2026-07-01 2026-09-30 0000844985 posc:SeriesAPreferredStocksMember 2025-01-01 2025-03-31 0000844985 posc:SeriesBPreferredStocksMember 2025-01-01 2025-03-31 0000844985 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000844985 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000844985 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000844985 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0000844985 2025-01-01 2025-03-31 0000844985 posc:SeriesAPreferredStocksMember 2025-04-01 2025-06-30 0000844985 posc:SeriesBPreferredStocksMember 2025-04-01 2025-06-30 0000844985 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0000844985 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0000844985 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0000844985 us-gaap:TreasuryStockCommonMember 2025-04-01 2025-06-30 0000844985 2025-04-01 2025-06-30 0000844985 posc:SeriesAPreferredStocksMember 2025-07-01 2025-09-30 0000844985 posc:SeriesBPreferredStocksMember 2025-07-01 2025-09-30 0000844985 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0000844985 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0000844985 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0000844985 us-gaap:TreasuryStockCommonMember 2025-07-01 2025-09-30 0000844985 posc:SeriesAPreferredStocksMember 2026-09-30 0000844985 posc:SeriesBPreferredStocksMember 2026-09-30 0000844985 us-gaap:PreferredStockMember 2026-09-30 0000844985 us-gaap:CommonStockMember 2026-09-30 0000844985 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0000844985 us-gaap:RetainedEarningsMember 2026-09-30 0000844985 us-gaap:TreasuryStockCommonMember 2026-09-30 0000844985 posc:SeriesAPreferredStocksMember 2025-09-30 0000844985 posc:SeriesBPreferredStocksMember 2025-09-30 0000844985 us-gaap:CommonStockMember 2025-09-30 0000844985 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0000844985 us-gaap:RetainedEarningsMember 2025-09-30 0000844985 us-gaap:TreasuryStockCommonMember 2025-09-30 0000844985 2025-09-30 0000844985 us-gaap:NotesPayableOtherPayablesMember posc:SignificantStockholderMember 2026-09-30 0000844985 us-gaap:NotesPayableOtherPayablesMember posc:SignificantStockholderMember 2026-01-01 2026-09-30 0000844985 2025-01-01 2025-12-31 0000844985 2022-01-01 2022-12-31 0000844985 us-gaap:EquipmentMember 2025-01-01 2025-12-31 0000844985 posc:CustomerAMember 2026-01-01 2026-09-30 0000844985 posc:CustomerAMember 2025-01-01 2025-09-30 0000844985 posc:CustomerBMember 2026-01-01 2026-09-30 0000844985 posc:CustomerBMember 2025-01-01 2025-09-30 0000844985 posc:CustomerCMember 2026-01-01 2026-09-30 0000844985 posc:CustomerCMember 2025-01-01 2025-09-30 0000844985 posc:CustomerDMember 2026-01-01 2026-09-30 0000844985 posc:CustomerDMember 2025-01-01 2025-09-30 0000844985 posc:CustomerEMember 2026-01-01 2026-09-30 0000844985 posc:CustomerEMember 2025-01-01 2025-09-30 0000844985 us-gaap:ServiceMember 2026-07-01 2026-09-30 0000844985 us-gaap:ServiceMember 2025-07-01 2025-09-30 0000844985 us-gaap:ServiceMember 2026-01-01 2026-09-30 0000844985 us-gaap:ServiceMember 2025-01-01 2025-09-30 0000844985 us-gaap:EquipmentMember 2026-09-30 0000844985 us-gaap:EquipmentMember 2025-12-31 0000844985 posc:OtherMember 2026-09-30 0000844985 posc:OtherMember 2025-12-31 0000844985 posc:StockOptionsMember 2026-01-01 2026-09-30 0000844985 posc:StockOptionsMember 2025-01-01 2025-09-30 0000844985 us-gaap:WarrantMember 2026-01-01 2026-09-30 0000844985 us-gaap:WarrantMember 2025-01-01 2025-09-30 0000844985 us-gaap:SeriesAPreferredStockMember 2026-01-01 2026-09-30 0000844985 us-gaap:SeriesAPreferredStockMember 2025-01-01 2025-09-30 0000844985 us-gaap:SeriesBPreferredStockMember 2026-01-01 2026-09-30 0000844985 us-gaap:SeriesBPreferredStockMember 2025-01-01 2025-09-30 0000844985 us-gaap:CommonStockMember 2026-01-01 2026-09-30 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable1RelatedPartyMember 2026-01-01 2026-09-30 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable2RelatedPartyMember 2026-01-01 2026-09-30 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable3RelatedPartyMember 2026-01-01 2026-09-30 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable4RelatedPartyMember 2026-01-01 2026-09-30 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable5RelatedPartyMember 2026-01-01 2026-09-30 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable6RelatedPartyMember 2026-01-01 2026-09-30 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable1RelatedPartyMember 2026-09-30 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable2RelatedPartyMember 2026-09-30 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable3RelatedPartyMember 2026-09-30 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable4RelatedPartyMember 2026-09-30 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable5RelatedPartyMember 2026-09-30 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable6RelatedPartyMember 2026-09-30 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable1RelatedPartyMember 2024-12-31 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable2RelatedPartyMember 2024-12-31 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable3RelatedPartyMember 2024-12-31 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable4RelatedPartyMember 2024-12-31 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable5RelatedPartyMember 2024-12-31 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable6RelatedPartyMember 2024-12-31 0000844985 posc:ShareholderAndDirectorMember us-gaap:NotesPayableCurrent 2024-12-31 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable1RelatedPartyMember 2025-01-01 2025-12-31 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable2RelatedPartyMember 2025-01-01 2025-12-31 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable3RelatedPartyMember 2025-01-01 2025-12-31 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable4RelatedPartyMember 2025-01-01 2025-12-31 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable5RelatedPartyMember 2025-01-01 2025-12-31 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable6RelatedPartyMember 2025-01-01 2025-12-31 0000844985 posc:ShareholderAndDirectorMember us-gaap:NotesPayableCurrent 2025-01-01 2025-12-31 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable1RelatedPartyMember 2025-12-31 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable2RelatedPartyMember 2025-12-31 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable3RelatedPartyMember 2025-12-31 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable4RelatedPartyMember 2025-12-31 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable5RelatedPartyMember 2025-12-31 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable6RelatedPartyMember 2025-12-31 0000844985 posc:ShareholderAndDirectorMember us-gaap:NotesPayableCurrent 2025-12-31 0000844985 posc:ShareholderAndDirectorMember us-gaap:NotesPayableCurrent 2026-01-01 2026-09-30 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable1RelatedPartyMember posc:ThreeLaksWarrantsMember 2026-01-01 2026-09-30 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable2RelatedPartyMember posc:ThreeLaksWarrantsMember 2026-01-01 2026-09-30 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable3RelatedPartyMember posc:ThreeLaksWarrantsMember 2026-01-01 2026-09-30 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable4RelatedPartyMember posc:ThreeLaksWarrantsMember 2026-01-01 2026-09-30 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable5RelatedPartyMember posc:ThreeLaksWarrantsMember 2026-01-01 2026-09-30 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable6RelatedPartyMember posc:ThreeLaksWarrantsMember 2026-01-01 2026-09-30 0000844985 posc:ShareholderAndDirectorMember us-gaap:NotesPayableCurrent posc:ThreeLaksWarrantsMember 2026-01-01 2026-09-30 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable1RelatedPartyMember posc:EightyThousandWarrantsMember 2026-01-01 2026-09-30 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable2RelatedPartyMember posc:EightyThousandWarrantsMember 2026-01-01 2026-09-30 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable3RelatedPartyMember posc:EightyThousandWarrantsMember 2026-01-01 2026-09-30 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable4RelatedPartyMember posc:EightyThousandWarrantsMember 2026-01-01 2026-09-30 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable5RelatedPartyMember posc:EightyThousandWarrantsMember 2026-01-01 2026-09-30 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable6RelatedPartyMember posc:EightyThousandWarrantsMember 2026-01-01 2026-09-30 0000844985 posc:ShareholderAndDirectorMember us-gaap:NotesPayableCurrent posc:EightyThousandWarrantsMember 2026-01-01 2026-09-30 0000844985 posc:ShareholderAndDirectorMember us-gaap:NotesPayableCurrent 2026-09-30 0000844985 posc:NotePayable1RelatedPartyMember 2026-09-30 0000844985 posc:NotePayable1RelatedPartyMember 2025-12-31 0000844985 posc:ShareholderAndDirectorMember 2023-04-30 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable2RelatedPartyMember 2023-04-30 0000844985 2023-12-31 0000844985 2024-03-31 0000844985 posc:ShareholderAndDirectorMember 2024-03-31 0000844985 2024-01-01 2024-12-31 0000844985 posc:ShareholderAndDirectorMember 2024-09-30 0000844985 posc:WarrantsMember 2025-01-01 2025-12-31 0000844985 posc:ShareholderAndDirectorMember 2024-08-31 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable3RelatedPartyMember 2024-08-31 0000844985 posc:ShareholderAndDirectorMember 2024-12-31 0000844985 posc:ShareholderAndDirectorMember 2025-02-28 0000844985 posc:ShareholderAndDirectorMember posc:NotePayable4RelatedPartyMember 2025-02-28 0000844985 posc:TwoRelatedPartiesNote5And6Member 2026-09-30 0000844985 posc:NotePayable5RelatedPartyMember 2026-09-30 2026-09-30 0000844985 posc:BoardOfDirectorsMember posc:NotePayable6RelatedPartyMember 2026-09-30 2026-09-30 0000844985 posc:NotePayable5And6RelatedPartyMember 2026-09-30 2026-09-30 0000844985 posc:NotePayable6RelatedPartyMember 2026-09-30 2026-09-30 0000844985 posc:NotePayable5RelatedPartyMember us-gaap:WarrantMember 2026-09-30 0000844985 posc:NotePayable6RelatedPartyMember us-gaap:CommonStockMember 2026-09-30 0000844985 2026-08-13 0000844985 2026-08-02 2026-08-13 0000844985 srt:MaximumMember 2026-08-02 2026-08-13 0000844985 srt:MinimumMember 2026-08-02 2026-08-13 0000844985 us-gaap:WarrantMember 2026-08-02 2026-08-13 0000844985 us-gaap:WarrantMember 2026-08-13 0000844985 2025-07-01 2025-07-08 0000844985 2025-06-26 2025-08-31 0000844985 2022-03-01 2022-03-17 0000844985 posc:FirstThreeYearsMember 2022-03-17 0000844985 posc:LastTwoYearsMember 2022-03-17 0000844985 2025-10-27 0000844985 us-gaap:SeriesAPreferredStockMember 2026-03-18 0000844985 us-gaap:SeriesBPreferredStockMember 2026-03-18 0000844985 us-gaap:SeriesCPreferredStockMember 2026-03-18 0000844985 us-gaap:SeriesDPreferredStockMember 2026-03-18 0000844985 us-gaap:SeriesEPreferredStockMember 2026-03-18 0000844985 us-gaap:SeriesFPreferredStockMember 2026-03-18 0000844985 us-gaap:SeriesGPreferredStockMember 2026-03-18 0000844985 us-gaap:SeriesHPreferredStockMember 2026-03-18 0000844985 posc:SeriesSPreferredStockMember 2026-03-18 0000844985 us-gaap:SeriesAPreferredStockMember 2025-12-31 0000844985 us-gaap:SeriesAPreferredStockMember 2026-09-30 0000844985 us-gaap:SeriesBPreferredStockMember 2026-09-30 0000844985 us-gaap:SeriesAPreferredStockMember 2025-10-30 0000844985 us-gaap:SeriesBPreferredStockMember 2025-10-30 0000844985 us-gaap:SeriesAPreferredStockMember 2025-10-29 2025-10-30 0000844985 us-gaap:SeriesBPreferredStockMember 2025-10-29 2025-10-30 0000844985 posc:ServicesMember 2026-01-01 2026-09-30 0000844985 posc:ServicesMember us-gaap:CommonStockMember 2026-01-01 2026-09-30 0000844985 posc:ServicesMember 2026-09-30 0000844985 us-gaap:CommonStockMember 2026-01-01 2026-09-30 0000844985 posc:ExerciseWarrantsMember 2026-01-01 2026-09-30 0000844985 posc:ExerciseWarrantsMember us-gaap:CommonStockMember 2026-01-01 2026-09-30 0000844985 posc:CashPaymentsMember 2025-12-31 0000844985 srt:MinimumMember posc:CashPaymentsMember 2025-12-31 0000844985 srt:MaximumMember posc:CashPaymentsMember 2025-12-31 0000844985 posc:CashPaymentsMember us-gaap:RelatedPartyMember 2025-12-31 0000844985 posc:CashPaymentsMember posc:PrincipalStockholderMember 2025-12-31 0000844985 us-gaap:RelatedPartyMember 2026-01-01 2026-09-30 0000844985 us-gaap:RelatedPartyMember srt:MinimumMember 2026-01-01 2026-09-30 0000844985 us-gaap:RelatedPartyMember srt:MaximumMember 2026-01-01 2026-09-30 0000844985 us-gaap:RelatedPartyMember 2026-09-30 0000844985 2021-05-31 0000844985 2025-11-05 0000844985 2025-11-04 2025-11-05 0000844985 posc:BoardOfDirectorsChairmanAndPresidentMember 2025-11-05 0000844985 posc:BoardsOfDirectorsMember 2025-11-05 0000844985 us-gaap:WarrantMember 2024-12-31 0000844985 us-gaap:WarrantMember 2024-01-01 2024-12-31 0000844985 us-gaap:WarrantMember 2025-01-01 2025-12-31 0000844985 us-gaap:WarrantMember 2025-12-31 0000844985 us-gaap:WarrantMember 2026-09-30 0000844985 us-gaap:LineOfCreditMember posc:SignificantStockholderMember 2026-08-13 0000844985 posc:SignificantStockholderOneMember us-gaap:CommercialPaperMember 2026-09-30 0000844985 posc:BoardOfDirectorsMember us-gaap:CommercialPaperMember 2026-09-30 0000844985 us-gaap:LineOfCreditMember 2026-08-12 2026-08-13 0000844985 us-gaap:LineOfCreditMember 2026-09-30 0000844985 us-gaap:CommercialPaperMember 2026-01-01 2026-09-30 0000844985 us-gaap:CommercialPaperMember 2026-09-30 0000844985 2026-09-02 0000844985 posc:WarrantsMember 2026-09-02 0000844985 posc:FairValueOfWarrantsMember 2026-08-12 2026-08-13 0000844985 posc:FairValueOfWarrantsMember 2026-01-01 2026-09-30 0000844985 posc:FairValueOfWarrantsMember 2026-08-13 0000844985 posc:FairValueOfWarrantsMember 2026-09-30 0000844985 us-gaap:LineOfCreditMember 2026-09-26 0000844985 us-gaap:LineOfCreditMember 2026-09-25 2026-09-26 0000844985 us-gaap:CommercialPaperMember us-gaap:SubsequentEventMember 2026-09-29 2026-10-01 0000844985 us-gaap:SubsequentEventMember 2026-10-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2026

 

or

 

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to _______

 

Commission File Number 000-24092

 

POSITRON CORPORATION
(Exact name of registrant as specified in its charter)

 

Texas   76-0083622

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

     

3784 Commerce Ct, Suite 100

North Tonawanda, NY

  14120
(Address of principal executive offices)   (Zip Code)

 

(317) 576-0183

(Registrant’s telephone number, including area code)

 

 

(Former name, former address, and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.0001 POSC OTC Markets

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated Filer ☒ Smaller reporting company ☒
    Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) ☐ Yes ☒ No

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

As of November 13, 2026 the registrant had 33,096,326 shares of common stock, par value $0.0001 per share, outstanding.

 

 

 

 

 

 

TABLE OF CONTENTS

 

PART I - FINANCIAL INFORMATION   F-1  
         
Item 1. Condensed Financial Statements (Unaudited)   F-1  
         
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations   4  
         
Item 3. Quantitative and Qualitative Disclosures About Market Risk   12  
         
Item 4. Controls and Procedures   12  
       
PART II - OTHER INFORMATION   13  
         
Item 1. Legal Proceedings   13  
         
Item 1A. Risk Factors   13  
         
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds   13  
         
Item 3. Defaults Upon Senior Securities   13  
         
Item 4. Mine Safety Disclosures   13  
         
Item 5. Other Information   13  
         
Item 6. Exhibits   14  
         
SIGNATURES   15  

 

2

 

 

FORWARD-LOOKING STATEMENTS

 

This quarterly report contains forward-looking statements. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.

 

Our unaudited financial statements are prepared in accordance with United States Generally Accepted Accounting Principles. The following discussion should be read in conjunction with our unaudited financial statements and the related notes that appear elsewhere in this quarterly report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in Part I, Item 1A, “Risk Factors”, in our Annual Report on Form 10-K for the year ended December 31, 2025, and in our other filings with the Securities and Exchange Commission, as well as those discussed elsewhere in this quarterly report.

 

In this quarterly report, unless otherwise specified, all dollar amounts are expressed in United States dollars and all references to “common shares” refer to shares of our common stock.

 

As used in this quarterly report, the terms “we”, “us”, “our” and the “Company” mean Positron Corporation, unless otherwise indicated.

 

3

 

 

PART I - FINANCIAL STATEMENTS

 

Item 1. Financial Statements

 

Positron Corporation

 

    Page(s)
     
Balance Sheets (Unaudited)   F-2
     
Statements of Operations (Unaudited)   F-3
     
Statements of Changes in Stockholders’ Equity (Deficit) (Unaudited)   F-4 - F-5
     
Statements of Cash Flows (Unaudited)   F-6
     
Notes to Financial Statements (Unaudited)   F-7 - F-53

 

F-1

 

 

Positron Corporation
Balance Sheets
(Unaudited)

 

   September 30, 2026   December 31, 2025 
  

(Unaudited)

      
Assets 
           
Current Assets          
Cash and cash equivalents  $1,925,653   $2,520,466 
Accounts receivable   20,994    8,333 
Inventory   680,000    680,000 
Prepaids and other   42,277    130,387 
Deferred financing costs - related party - net   210,084    - 
Total Current Assets   2,879,008    3,339,186 
           
Property and equipment - net   77,326    105,752 
           
Operating lease - right-of-use asset   150,306    179,711 
           
Deposits   375,000    375,000 
           
Deferred financing costs - related party - net   175,079    - 
           
Total Assets  $3,656,719   $3,999,649 
           
Liabilities and Stockholders’ Equity (Deficit) 
           
Current Liabilities          
Accounts payable and accrued expenses  $435,300   $81,512 
Accounts payable and accrued expenses - related party   474,236    407,017 
Deferred revenue   210,000    120,000 
Notes payable - related parties - net   2,362,571    1,200,000 
Operating lease liability   34,440    30,612 
Convertible advance payable   563,000    563,000 
Total Current Liabilities   4,079,547    2,402,141 
           
Long Term Liabilities          
Operating lease liability   127,395    153,686 
Total Long Term Liabilities   127,395    153,686 
           
Total Liabilities   4,206,942    2,555,827 
           
Commitments and Contingencies  (Note 6)   —    — 
           
Stockholders’ Equity (Deficit)        
Preferred stock - $0.0001 par value; 10,000,000 authorized   —    — 
Common stock - $0.0001 par value, 100,000,000 shares authorized 33,096,326 and 32,799,451 shares issued and outstanding, respectively   3,310    3,280 
Additional paid-in capital   147,555,072    146,377,996 
Accumulated deficit   (148,108,230)   (144,937,079)
Less: treasury stock at cost - 750 and 750 shares, respectively   (375)   (375)
Total Stockholders’ Equity (Deficit)   (550,223)   1,443,822 
           
Total Liabilities and Stockholders’ Equity (Deficit)  $3,656,719   $3,999,649 

 

The accompanying notes are an integral part of these unaudited financial statements

 

F-2

 

 

Positron Corporation
Statements of Operations
(Unaudited)

 

                   
   For the Three Months Ended September 30,   For the Nine Months Ended September 30, 
   2026   2025   2026   2025 
                 
Sales  $102,667   $111,000   $325,489   $350,452 
                     
Cost of sales   492,108    367,161    1,506,659    1,146,626 
                     
Gross loss   (389,441)   (256,161)   (1,181,170)   (796,174)
                     
General and administrative expenses   527,947    749,992    1,905,089    2,803,258 
                     
Loss from operations   (917,388)   (1,006,153)   (3,086,259)   (3,599,432)
                     
Other income (expense)                    
Interest expense - related parties (including amortization of deferred financing costs)   (57,069)   (30,247)   (102,233)   (95,091)
Interest and other income   2,475    7,478    17,341    7,478 
Loss on lease termination   -    (15,018)   -    (15,018)
Total other income (expense) - net   (54,594)   (37,787)   (84,892)   (102,631)
                     
Net loss  $(971,982)  $(1,043,940)  $(3,171,151)  $(3,702,063)
                     
Loss per share - basic and diluted  $(0.03)  $(0.03)  $(0.10)  $(0.12)
                     
Weighted average number of shares - basic and diluted   32,922,413    31,305,008    32,868,006    30,586,449 

 

The accompanying notes are an integral part of these unaudited financial statements

 

F-3

 

 

Positron Corporation
Statements of Changes in Stockholders’ Equity (Deficit)
For the Three and Nine Months Ended September 30, 2026

(Unaudited)

 

                   Additional               Total 
       Preferred Stock   Common Stock   Paid-in   Accumulated   Treasury Stock   Stockholders’ 
       Shares   Amount   Shares   Amount   Capital   Deficit   Shares   Amount   Equity (Deficit) 
                                         
December 31, 2025  - -  -   $-    32,799,451   $3,280   $146,377,996   $(144,937,079)   750   $(375)  $1,443,822 
                                                  
Stock issued for services rendered ($1.89/share)       -    -    50,000    5    94,495    -    -    -    94,500 
                                                  
Net loss  - -  -    -    -    -    -    (1,377,769)   -    -    (1,377,769)
                                                  
March 31, 2026  - -  -    -    32,849,451    3,285    146,472,491    (146,314,848)   750    (375)   160,553 
                                                  
Cancellation of shares       -    -    (3,125)   -    -    -    -    -    - 
                                                  
Net loss  - -  -    -    -    -    -    (821,400)   -    -    (821,400)
                                                  
June 30, 2026  - -  -    -    32,846,326    3,285    146,472,491    (147,136,248)   750    (375)   (660,847)
                                                  
Proceeds from exercise of warrants - related party ($1/share)       -    -    250,000    25    249,975    -    -    -    250,000 
                                                  
Warrants issued with notes payable - related parties       -    -    -    -    412,429    -    -    -    412,429 
                                                  
Warrants issued for line of credit - related party       -    -    -    -    420,177    -    -    -    420,177 
                                                  
Net loss  - -  -    -    -    -    -    (971,982)   -    -    (971,982)
                                                  
September 30, 2026  - -  -   $-    33,096,326   $3,310   $147,555,072   $(148,108,230)   750   $(375)  $(550,223)

 

The accompanying notes are an integral part of these unaudited financial statements

 

F-4

 

 

Positron Corporation
Statements of Changes in Stockholders’ Equity (Deficit)
For the Three and Nine Months Ended September 30, 2025
(Unaudited)

 

                                         Additional               Total 
   Series A - Preferred Stock   Series B - Preferred Stock   Common Stock   Paid-in   Accumulated   Treasury Stock   Stockholders’ 
   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   Shares   Amount   Equity (Deficit) 
                                             
December 31, 2024   435,085   $435,085    192,000   $192,000    27,305,008   $2,731   $133,047,521   $(134,333,687)   750   $(375)  $(656,725)
                                                        
Stock issued for cash ($1/share)   -    -    -    -    8,000,000    800    7,999,200    -    -    -    8,000,000 
                                                        
Cash paid to repurchase and retire common stock ($0.60 - $0.75/share)   -    -    -    -    (4,000,000)   (400)   (2,499,600)   -    -    -    (2,500,000)
                                                        
Imputed interest expense on debt - related parties   -    -    -    -    -    -    2,937    -    -    -    2,937 
                                                        
Forgiveness of accrued interest payable - related party   -    -    -    -    -    -    41,414    -    -    -    41,414 
                                                        
Net loss   -    -    -    -    -    -    -    (1,467,381)   -    -    (1,467,381)
                                                        
March 31, 2025   435,085   $435,085    192,000   $192,000    31,305,008   $3,131   $138,591,472   $(135,801,068)   750   $(375)  $3,420,245 
                                                        
Stock issued for services rendered ($1.77/share)   -    -    -    -    100,000    10    176,990    -    -    -    177,000 
                                                        
Net loss   -    -    -    -    -    -    -    (1,190,742)   -    -    (1,190,742)
                                                        
June 30, 2025   435,085   $435,085    192,000   $192,000    31,405,008   $3,141   $138,768,462   $(136,991,810)   750   $(375)  $2,406,503 
                                                        
Net loss   -    -    -    -    -    -    -    (1,043,940)   -    -    (1,043,940)
                                                        
September 30, 2025   435,085   $435,085    192,000   $192,000    31,405,008   $3,141   $138,768,462   $(138,035,750)   750   $(375)  $1,362,563 

 

The accompanying notes are an integral part of these unaudited financial statements

 

F-5

 

 

Positron Corporation
Statements of Cash Flows
(Unaudited)

 

          
   For the Nine Months Ended September 30, 
   2026   2025 
         
Operating activities          
Net loss  $(3,171,151)  $(3,702,063)
Adjustments to reconcile net loss to net cash used in operations          
Amortization of operating lease - right-of-use asset   29,405    17,283 
Depreciation expense   28,426    17,776 
Amortization of deferred financing costs - related party   35,014    - 
Stock issued for services   94,500    177,000 
Loss on lease termination   -    15,018 
Imputed interest expense on debt - related parties   -    2,937 
Cash paid for lease termination   -    (20,000)
Changes in operating assets and liabilities          
(Increase) decrease in          
Accounts Receivable   (12,661)   8,334 
Inventory   -    - 
Prepaids and other   88,110    (15,390)
Increase (decrease) in          
Accounts payable and accrued expenses   353,788    5,670 
Accounts payable and accrued expenses - related party   67,219    92,154 
Deferred revenue   90,000    53,670 
Operating lease liability   (22,463)   (15,646)
Net cash used in operating activities   (2,419,813)   (3,363,257)
           
Investing activities          
Purchase of fixed assets   -    (76,524)
Net cash used in investing activities   -    (76,524)
           
Financing activities          
Proceeds from issuance of common stock - related party   -    8,000,000 
Proceeds from exercise of warrants - related party   250,000    - 
Cash paid to repurchase and retire common stock   -    (2,500,000)
Proceeds from issuance of notes payable - related parties   1,900,000    100,000 
Repayments on notes payable - related party   (325,000)   (350,000)
Net cash provided by (used in) financing activities   1,825,000    5,250,000 
           
Net increase (decrease) in cash and cash equivalents   (594,813)   1,810,219 
           
Cash and cash equivalents - beginning of period   2,520,466    69,791 
           
Cash and cash equivalents - end of period  $1,925,653   $1,880,010 
           
Supplemental disclosure of cash flow information          
Cash paid for interest  $-   $- 
Cash paid for income tax  $-   $- 
           
Supplemental disclosure of non-cash investing and financing activities          
Warrants issued with notes payable - related parties (debt discount)  $412,429   $- 
Warrants issued for line of credit - related party (deferred financing cost)  $420,177   $- 
Forgiveness of accrued interest payable - related party  $-   $41,414 
Right-of-use asset obtained in exchange for new operating lease liability  $-   $196,049 
Termination of ROU operating lease asset and liability  $-   $28,228 

 

The accompanying notes are an integral part of these unaudited financial statements

 

F-6

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

Note 1 - Organization and Nature of Operations

 

Organization and Nature of Operations

 

Positron Corporation (collectively, “we,” “us,” “our” or the “Company”), is a Texas corporation originally incorporated on December 20, 1983.

 

Positron Corporation is a medical technology company that co-develops, manufactures, and sells PET and PET-CT imaging systems and related services to healthcare providers. The Company focuses on cardiac PET imaging and is expanding into broader clinical applications, including oncology. Positron collaborates with its strategic partner, Neusoft Medical Systems, to support product development, manufacturing, and innovation.

 

Basis of Presentation

 

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements (“U.S. GAAP”) and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements.

 

In the opinion of the Company’s management, the accompanying unaudited financial statements contain all of the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of September 30, 2026 and the results of operations and cash flows for the periods presented. The results of operations for the three and nine months ended September 30, 2026 are not necessarily indicative of the operating results for the full fiscal year or any future period.

 

These unaudited financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 31, 2026.

 

Management acknowledges its responsibility for the preparation of the accompanying unaudited financial statements which reflect all adjustments, consisting of normal recurring adjustments, considered necessary in its opinion for a fair statement of its financial position and the results of its operations for the periods presented.

 

F-7

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

Liquidity, Going Concern and Management’s Plans

 

These unaudited financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business.

 

As reflected in the accompanying unaudited financial statements, for the nine months ended September 30, 2026, the Company had:

 

●Net loss of $3,171,151; and

●Net cash used in operations was $2,419,813

 

Additionally, at September 30, 2026, the Company had:

 

●Accumulated deficit of $148,108,230;

●Stockholders’ deficit of $550,223;

●Working capital deficiency of $1,200,539;
  ● Notes payable - related parties of $2,775,000 in principal due within twelve (12) months, including $875,000 due December 31, 2026; and
  ● Convertible advance payable of $563,000 due on demand

 

The Company has cash on hand of $1,925,653 at September 30, 2026. The Company does not expect to generate sufficient revenues and positive cash flows from operations sufficiently to meet its current obligations. However, the Company may seek to raise debt or equity-based capital at favorable terms, though such terms are not certain.

 

On September 30, 2026, the Company issued notes payable to a significant stockholder and to an entity affiliated with a member of the Board of Directors in the aggregate principal amount of $1,900,000, maturing September 30, 2027. The Company also has a $2,000,000 line of credit with a significant stockholder, under which no advances had been drawn at September 30, 2026, subject to a maximum of $500,000 per calendar quarter (see Note 5).

 

These factors create substantial doubt about the Company’s ability to continue as a going concern within the twelve-month period subsequent to the date that these financial statements are issued. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

 

Management’s strategic plans include the following:

 

●Execute business operations more fully during the current year;

●Expand its reach within nuclear cardiology with the launch of our PET-CT system which provides greater features and functions now available to nuclear cardiologists and their diagnostic capabilities;

●Enter the vast oncology market with its new PET-CT system with a faster, smaller, more economical solution for practices, hospitals, and patients;

 

F-8

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

●Explore and execute prospective strategic and partnership opportunities; and

●Pursue to “Up-List” to a more prominent publicly reporting exchange.

 

Note 2 - Summary of Significant Accounting Policies

 

Business Segments and Expense Disclosure

 

The Company follows Financial Accounting Standards Board (FASB) ASC 280, Segment Reporting, which requires public entities to report financial and descriptive information about their reportable operating segments.

 

FASB ASC 280-10-50-1 states that an operating segment is a component of a public entity that:

 

●Engages in business activities from which it may earn revenues and incur expenses;

●Has operating results that are regularly reviewed by the Chief Operating Decision Maker (CODM), who is the Company’s Chief Executive Officer, to make decisions about resource allocation and performance assessment; and

●Has discrete financial information available.

 

The Company operates as one (1) operating segment and one (1) reportable segment. The Company’s chief operating decision maker (CODM) is its Chief Executive Officer. The CODM manages and reviews the business as a whole rather than by distinct business components, and uses net loss, as reported on the accompanying Statements of Operations, to assess performance and allocate resources. The significant segment expenses regularly provided to the CODM are cost of sales and general and administrative expenses, each presented separately on the accompanying Statements of Operations. Other segment items within net loss consist of interest expense, net, and amortization of deferred financing costs. The measure of segment assets is total assets as reported on the accompanying Balance Sheets. 

 

In November 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which requires all public entities, including public entities with a single reportable segment, to provide in interim and annual periods one or more measures of segment profit or loss used by the chief operating decision maker to allocate resources and assess performance. Additionally, the standard requires disclosures of significant segment expenses and other segment items as well as incremental qualitative disclosures.

 

The Company adopted ASU 2023-07 for its annual reporting period ended December 31, 2024 and for interim periods beginning January 1, 2025, on a retrospective basis. The adoption did not change the way the Company identifies its reportable segments and, accordingly, did not have a material impact on the Company’s segment-related disclosures.

 

F-9

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

 SEPTEMBER 30, 2026 AND 2025

 (UNAUDITED)

 

 

Use of Estimates and Assumptions

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the recognition of revenues and expenses during the reporting period. Actual results may differ from these estimates, and such differences could be material.

 

Changes in estimates are recorded in the period in which they become known and are accounted for prospectively. The Company bases its estimates on historical experience, industry trends, and other relevant factors, incorporating both quantitative and qualitative assessments that it believes are reasonable under the circumstances.

 

Significant estimates during the nine months ended September 30, 2026 and 2025 include:

 

●Allowance for doubtful accounts and other receivables

●Inventory reserves and classifications

●Valuation of equity based instruments

●Estimated useful lives of property and equipment

●Implicit interest rate in right-of-use operating leases

●Uncertain tax positions

●Valuation allowance on deferred tax assets

 

Risks and Uncertainties

 

The Company operates in a highly competitive industry that is subject to intense market dynamics, shifting consumer demand, and economic fluctuations. The Company’s operations are exposed to significant financial, operational, and strategic risks, including potential business disruptions, supply chain constraints, and liquidity challenges.

 

In accordance with FASB ASC 275, “Risks and Uncertainties,” the Company evaluates and discloses risks that could materially affect its financial condition, results of operations, and business outlook. Key factors contributing to variability in sales and earnings include:

 

1.Industry Cyclicality – The Company’s financial performance is affected by industry trends, seasonality, and shifts in market demand.

 

F-10

 

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

2.Macroeconomic Conditions– Economic downturns, inflationary pressures, interest rate changes, global tariff policy, and geopolitical risks may impact consumer purchasing behavior and the Company’s revenue streams.

3.Pricing Volatility– The cost and availability of raw materials, supply chain disruptions, and competitive pricing pressures can lead to fluctuations in gross margins and profitability.

 

Given these uncertainties, the Company faces challenges in accurately forecasting financial performance and may experience material risks affecting liquidity, business continuity, and long-term strategic growth. The Company continuously assesses these risks and implements measures to mitigate their potential impact.

 

Fair Value of Financial Instruments

 

The Company accounts for financial instruments in accordance with Financial Accounting Standards Board (FASB) ASC 820, “Fair Value Measurements”, which establishes a framework for measuring fair value and requires related disclosures. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the Company’s principal market or, if none exists, the most advantageous market for the asset or liability.

 

Fair Value Hierarchy

 

FASB ASC 820 requires the use of observable inputs whenever available and establishes a three-tier hierarchy for measuring fair value:

 

●Level 1 – Quoted market prices (unadjusted) for identical assets or liabilities in active markets.

●Level 2 – Observable inputs other than quoted prices in active markets, such as quoted prices for similar assets and liabilities or inputs that are directly or indirectly observable.

●Level 3 – Unobservable inputs that require significant judgment, including management assumptions and estimates based on available market data.

 

The classification of an asset or liability within the hierarchy is based on the lowest level of input that is significant to the fair value measurement. Level 3 valuations generally require more judgment and complexity, often involving a combination of cost, market, or income approaches, as well as assumptions about market conditions, pricing, and other factors.

 

F-11

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

 SEPTEMBER 30, 2026 AND 2025

 (UNAUDITED)  

 

Fair Value Determination

 

The Company assesses the fair value of its financial instruments and, where appropriate, may engage external valuation specialists to assist in determining fair value. While management believes that recorded fair values are reasonable, they may not necessarily reflect net realizable values or future fair values.

 

Financial Instruments Carried at Historical Cost

 

The Company’s financial instruments—including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses (including related party balances)—are recorded at historical cost. As of September 30, 2026 and December 31, 2025, respectively, the carrying amounts of these instruments approximated their fair values due to their short-term maturities. The carrying amounts of notes payable - related parties, net of discount, and the convertible advance payable approximated their fair values at September 30, 2026 and December 31, 2025, respectively, because the notes mature within twelve (12) months and the advance is due on demand.

 

Cash and Cash Equivalents and Concentration of Credit Risk

 

For purposes of the statements of cash flows, the Company considers all highly liquid investments with original maturities of three months or less from the date of purchase, including money market accounts and short-term certificates of deposit, to be cash equivalents.

 

At September 30, 2026, the Company did not hold any cash equivalents.

 

At December 31, 2025, the Company’s cash equivalents consisted of a money market account.

 

The Company is exposed to credit risk on its cash and cash equivalents in the event of default by the financial institutions to the extent account balances exceed the amount insured by the FDIC, which is $250,000.

 

At September 30, 2026 and December 31, 2025, the Company had cash in excess of the insured FDIC limit of $1,675,878 and $2,272,502, respectively. From time to time the Company has amounts that exceed the FDIC insured amount but does not expect any non-performance.

 

Accounts Receivable

 

The Company accounts for accounts receivable in accordance with FASB ASC 326, “Financial Instruments – Credit Losses”. Receivables are recorded at their net realizable value, which represents the amount management expects to collect from outstanding customer balances.

 

F-12

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

The Company extends credit to customers based on an evaluation of their financial condition and other factors. The Company does not require collateral, and interest is not accrued on overdue accounts receivable.

 

Allowance for Expected Credit Losses

 

The Company has elected the practical expedient in Accounting Standards Update (ASU) 2025-05 for its current (short-term) accounts receivable. Under this practical expedient, the Company assumes that current economic conditions as of the balance sheet date will not change over the remaining life of these receivables when estimating expected credit losses.

 

Management periodically assesses the collectability of accounts receivable and establishes an allowance for expected credit losses as needed. The allowance is determined based on:

 

●A review of outstanding accounts,

●Historical collection experience, and

●Current economic conditions.

 

Accounts deemed uncollectible are written off against the allowance when determined to be uncollectible.

 

Allowance for expected credit losses was $0 at September 30, 2026 and December 31, 2025, respectively.

 

Inventory

 

Inventory consists of scanning equipment and is stated at the lower of cost or net realizable value (“LCNRV”) using the first-in, first-out (“FIFO”) method.

 

Management assesses the recoverability of inventory each reporting period and records write-downs to net realizable value when the carrying value exceeds estimated proceeds from sale, less costs to complete and sell.

 

Factors considered in this assessment include:

 

●Market conditions;

●Net realizable value based on estimated selling price and selling costs; and

●Inventory turnover trends.

 

During the year ended December 31, 2025, the Company recorded an inventory write-down of $576,862 (included in cost of sales) to reduce the carrying value of its scanning equipment to net realizable value. Net realizable value was determined based on the estimated selling price under an existing sales contract, less estimated costs to complete and sell the

 

F-13

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

equipment. A customer deposit related to this contract is recorded in deferred revenue (see the revenue recognition discussion below).

 

During the nine months ended September 30, 2026, the Company incurred $238,352 of additional equipment costs to ready the unit for sale and recorded a corresponding inventory write-down of $238,352, which is included in cost of goods sold.

 

The machine will be delivered to the customer upon completion of installment payments under an executed sale agreement and upon FDA clearance; the corresponding consideration received to date has been recorded as deferred revenue (see below).

 

At September 30, 2026 and December 31, 2025, inventory was as follows:

 

Schedule of Inventory

Classification  September 30, 2026   December 31, 2025 
Finished systems  $918,352   $1,256,862 
Less: writedown of inventory to net realizable value   (238,352)   (576,862)
Total Inventory  $680,000   $680,000 

 

Deposits

 

Deposits represent amounts paid to a third-party manufacturer toward the purchase of a PET-CT system, the recoverability of which is contingent upon successful equipment validation and U.S. Food and Drug Administration (FDA) clearance. Activity in deposits for the nine months ended September 30, 2026 and the year ended December 31, 2025 was as follows:

 

December 31, 2024  $375,000 
No activity   - 
December 31, 2025  $375,000 
No activity   - 
September 30, 2026  $375,000 

 

In 2022, the Company paid $1,000,000 for equipment from its manufacturing partner, Neusoft Medical Systems. In connection with the same transaction, the Company agreed to pay a Non-Recurring Engineering (NRE) Fee of $700,000 to the manufacturer for research, development, and technology transfer services, payable as follows:

 

●$210,000 paid in 2022; and

●$490,000 paid in 2025.

F-14

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

Because the equipment has not received FDA clearance, the $490,000 paid in 2025 was charged to general and administrative expense in the accompanying statements of operations for the year ended December 31, 2025.

 

If the equipment does not receive FDA clearance, the Company has the contractual right to return the inventory and obtain a refund of the $1,000,000 purchase price, less applicable shipping and handling costs. The manufacturer has also agreed to provide a one-year warranty on the equipment and related software, commencing upon closing of the equipment purchase.

 

Concentrations

 

The Company evaluates and discloses significant concentrations of risk in accordance with FASB ASC 275-10, “Risks and Uncertainties.” These risks may arise from customer concentrations, vendor reliance, geographic dependence, or other economic factors that could materially impact the Company’s financial position, results of operations, and cash flows.

 

A concentration exists when a single customer, supplier, or market accounts for a significant portion (typically greater than 10%) of the Company’s total revenues, accounts receivable, or vendor purchases.

 

For the nine months ended September 30, 2026 and 2025, five (5) customers each accounted for 10% or more of revenues, as follows:

 

   Nine Months Ended 
Customer  September 30, 2026   September 30, 2025 
Customer A   23.04%   21.40%
Customer B   21.66%   20.12%
Customer C   20.74%   19.26%
Customer D   20.48%   21.40%
Customer E   13.83%   12.84%
Total   99.75%   95.02%

 

Property and Equipment

 

Property and equipment are recorded at cost, net of accumulated depreciation, in accordance with FASB ASC 360, “Property, Plant, and Equipment.” Depreciation is calculated using the straight-line method over the estimated useful lives of the assets.

 

Repairs and maintenance expenditures that do not materially extend the useful life of an asset are expensed as incurred. Significant improvements or upgrades that increase the asset’s productivity, efficiency, or useful life are capitalized.

 

Upon disposal or sale of property and equipment, the cost and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is recognized in the statement of operations.

 

The Company evaluates the carrying value of property and equipment whenever events or changes in circumstances indicate that the asset may be impaired. If impairment indicators exist, the Company assesses recoverability based on the undiscounted future cash flows

F-15

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

 SEPTEMBER 30, 2026 AND 2025

 (UNAUDITED)  

 

expected from the use and disposition of the asset. If the carrying amount exceeds the estimated recoverable amount, an impairment loss is recognized.

 

Financial Instruments with Characteristics of Both Liabilities and Equity

 

The Company evaluates equity or liability classification for freestanding financial instruments, including convertible preferred stock, warrants, and options, pursuant to the guidance under FASB ASC Topic 480, Distinguishing Liabilities from Equity (“ASC 480”). The Company classifies as liabilities all freestanding financial instruments that are (i) mandatorily redeemable, (ii) represent an obligation to repurchase the Company’s equity shares by transferring assets, or (iii) represent an unconditional obligation (or conditional obligation if the financial instrument is not an outstanding share) to issue a variable number of shares predominantly based on a fixed monetary amount, variations in something other than the fair value of the Company’s equity shares, or variations inversely related to changes in fair value of the Company’s equity shares.

 

If a freestanding financial instrument does not represent an outstanding equity share and does not meet liability classification under ASC 480, the Company then assesses whether the freestanding financial instrument is indexed to its own stock and meets equity classification pursuant to FASB ASC 815-40, “Contracts in Entity’s Own Equity” (“ASC 815”).

 

The Company further assesses whether the freestanding financial instruments should be classified as temporary equity. Freestanding financial instruments that are redeemable for cash or other assets at a fixed or determinable date, at the option of the holder, or upon the occurrence of an event are classified in temporary equity in accordance with FASB ASC 480. Otherwise, the freestanding financial instruments are classified in permanent equity.

 

Conversion and Extinguishment of Derivative Liabilities

 

When a debt instrument with an embedded conversion option (e.g., convertible debt or warrants) is converted into shares of common stock or repaid, the Company:

 

●Records the newly issued shares at fair value;

●Derecognizes all related debt, derivative liabilities, and unamortized debt discounts; and

●Recognizes a gain or loss on debt extinguishment, if applicable.

 

For equity-based derivative liabilities (e.g., warrants) that are extinguished, any remaining liability balance is reclassified to additional paid-in capital.

 

F-16

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

Original Issue Discounts and Other Debt Discounts

 

The Company accounts for original issue discounts (OID) and other debt discounts in accordance with FASB ASC 835-30, “Interest—Imputation of Interest”. These discounts are recorded as a reduction of the carrying amount of the related debt and are amortized to interest expense over the term of the debt using the effective interest method, unless the straight-line method is materially similar.

 

Original Issue Discounts (OID)

 

For certain notes issued, the Company may provide the debt holder with an original issue discount (OID), which is recorded as a debt discount, reducing the face value of the note. The discount is amortized to interest expense over the term of the debt in the Statements of Operations.

 

Stock and Other Equity Issued with Debt

 

The Company may issue common stock or other equity instruments in connection with debt issuance. When stock is issued, it is recorded at relative fair value and treated as a debt discount, reducing the carrying amount of the note. These discounts are amortized to interest expense over the life of the debt.

 

The combined debt discounts, including OID and stock-related discounts, cannot exceed the face amount of the debt.

 

Debt Issuance Costs

 

Debt issuance costs, including fees paid to lenders or third parties, are capitalized as a debt discount and amortized to interest expense over the life of the debt. These costs are presented as a direct deduction from the carrying amount of the debt liability rather than as a separate asset.

 

Debt issuance costs of a line-of-credit arrangement are deferred and presented as an asset, current to the extent amortized within twelve (12) months of the balance sheet date and non-current for the remainder, and are amortized to interest expense on a straight-line basis over the term of the arrangement regardless of whether any borrowings are outstanding.

 

Warranties and Maintenance Contracts

 

Product Warranties

 

The Company provides an assurance-type warranty on its products covering defects in design, materials, and workmanship for a period of one year from customer acceptance.

F-17

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

Assurance-type warranties do not represent a separate performance obligation under ASC 606; rather, the estimated cost of fulfilling the warranty obligation is accrued at the time of product delivery in accordance with ASC 460-10-25-5 and ASC 450-20-25, when the obligation is probable and reasonably estimable.

 

The warranty provision is based on historical trends in defect nature, frequency, and average cost of claims for each product line. These estimates are reassessed each reporting period using the best available information, and adjustments are made as necessary.

 

Historically, the Company has incurred insignificant warranty-related costs. At September 30, 2026 and December 31, 2025, no warranty liability was recorded, as the estimated obligation was deemed immaterial.

 

Certain components used in the Company’s products are covered under supplier-provided limited warranties, which include replacement and service coverage for parts. The Company does not have direct responsibility for these supplier warranties.

 

As of September 30, 2026 and December 31, 2025, the Company is not aware of any pending or asserted claims related to product warranty obligations.

 

Maintenance Contracts

 

The Company separately offers post-delivery maintenance contracts to customers. Maintenance contracts are distinct from the Company’s assurance-type product warranty and represent separate performance obligations under ASC 606. Revenue attributable to maintenance contracts is deferred at contract inception and recognized ratably over the maintenance period as the related services are performed. At September 30, 2026 and December 31, 2025, no maintenance contract revenue was deferred.

 

Treasury Stock

 

The Company accounts for treasury stock transactions under the cost method in accordance with FASB ASC 505-30, “Treasury Stock”. Under this method, when the Company repurchases its own shares, the full acquisition cost is recorded as a reduction to stockholders’ equity under the treasury stock account. These shares remain issued but are not considered outstanding and do not participate in dividends or earnings per share calculations.

 

As of September 30, 2026 and December 31, 2025, respectively, the Company had 750 shares of treasury stock recorded at an aggregate cost of $375.

 

F-18

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

 SEPTEMBER 30, 2026 AND 2025

 (UNAUDITED)  

 

Right of Use Assets and Lease Obligations

 

The Company accounts for right-of-use (ROU) assets and lease liabilities in accordance with FASB ASC 842, “Leases”. These amounts reflect the present value of the Company’s estimated future minimum lease payments over the lease term, including any reasonably certain renewal options, discounted using a collateralized incremental borrowing rate.

 

The Company classifies its leases as either operating or finance leases. The Company’s leases primarily consist of operating leases, which are included as Right-of-Use Assets and Operating Lease Liabilities on the balance sheet.

 

Short-Term Leases

 

The Company has elected the short-term lease exemption, whereby leases with a term of 12 months or less are not recorded on the balance sheet. Instead, lease payments are expensed on a straight-line basis over the lease term.

 

Lease Term and Renewal Options

 

In determining the lease term, the Company evaluates whether renewal options are reasonably certain to be exercised. Factors considered include:

 

●The useful life of leasehold improvements relative to the lease term,

●The economic performance of the business at the leased location,

●The comparative cost of renewal rates versus market rates, and

●The presence of any significant economic penalties for non-renewal.

 

If a renewal option is reasonably certain to be exercised, the right-of-use (ROU) asset and lease liability include the additional lease payments. The Company’s operating leases may contain renewal options and do not contain residual value guarantees. Management does not expect to exercise any renewal options, and renewal periods are therefore excluded from the measurement of lease liabilities.

 

Discount Rate and Lease Liability Measurement

 

Since the implicit rate in the leases is not readily determinable, the Company applies an incremental borrowing rate that represents the rate it would incur to borrow on a collateralized basis over a similar term and currency environment.

 

F-19

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

Lease Impairment

 

The Company evaluates ROU assets for impairment indicators whenever events or changes in circumstances suggest the carrying amount may not be recoverable.

 

See Note 6 for further discussion on lease cancellation during the year ended December 31, 2025.

 

Revenue Recognition

 

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. Revenue is recognized when or as control of promised goods or services is transferred to the customer in an amount that reflects the consideration the Company expects to receive in exchange for those goods or services. The Company applies the following five-step model:

 

(i) identify the contract with a customer; 

(ii) identify the performance obligations in the contract; 

(iii) determine the transaction price; 

(iv) allocate the transaction price to the performance obligations in the contract; and 

(v) recognize revenue when, or as, performance obligations are satisfied.

 

Nature of Services and Performance Obligations

 

The Company generates revenue primarily from clinical, technical, and maintenance service contracts that provide customers with ongoing product support and from sales of equipment. These contracts are generally one-year agreements that automatically renew for successive one-year periods unless terminated by either party with at least 90 days’ notice. The Company considers only the noncancelable initial term and any renewal periods for which the customer has a material right when determining the contract term and performance obligations.

 

Each maintenance contract represents a single distinct performance obligation. The various service elements - including priority response, 24/7 clinical and technical support, parts and labor, preventative maintenance, software upgrades, uptime guarantees, remote diagnostic capabilities, daily quality assurance inspections, and applications training - are highly integrated and interdependent. They are not separately identifiable from one another and are accounted for as a single stand-ready performance obligation that is satisfied continuously over the contract term.

F-20

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

Significant Judgments

 

In applying ASC 606, the Company makes the following significant judgments that affect the timing and amount of revenue recognized:

 

(i) the Company concluded that all services under each maintenance contract constitute a single performance obligation because they are highly interrelated and provide a combined integrated service to the customer;

 

(ii) for maintenance contracts, the Company uses a time-based, straight-line output method to measure progress, which it has determined faithfully depicts the Company’s performance as the customer simultaneously receives and consumes the benefits of the services; and

 

(iii) for equipment sales, the Company applies judgment in assessing when control transfers to the customer.

 

No changes to these judgments have occurred during the periods presented.

 

Transaction Price and Allocation

 

The transaction price is the fixed fee stated in each contract. The Company generally does not offer refunds, rebates, discounts, or variable pricing incentives. Maintenance contract fees are typically billed monthly in advance with payment due within 30 days. As permitted by the practical expedient in ASC 606-10-32-18, the Company does not adjust the transaction price for the effects of a significant financing component when the period between transfer of control of the good or service and customer payment is one year or less. Because each contract contains a single performance obligation, the entire transaction price is allocated to that obligation.

 

Revenue Recognition – Timing

 

The Company recognizes revenue either over time or at a point in time depending on the nature of the performance obligation.

 

Maintenance contract revenue is recognized over time as the customer simultaneously receives and consumes the benefits of the services as they are provided. Revenue is recognized ratably on a straight-line basis over the contract term. Amounts received in advance of services being provided are recorded as deferred revenue and recognized as revenue as the related performance obligations are satisfied.

F-21

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

 SEPTEMBER 30, 2026 AND 2025

 (UNAUDITED)  

 

Equipment sale revenue is recognized at a point in time when control of the equipment transfers to the customer, which occurs upon physical delivery and acceptance of the equipment and where collection is probable. In the three and nine months ended September 30, 2026 and 2025, no equipment sale revenue had been recognized, as the conditions for transfer of control had not yet been met.

 

Principal vs. Agent Considerations

 

The Company has determined that it acts as a principal in all revenue transactions. The Company controls the services prior to transfer to the customer, is responsible for fulfilling all contractual obligations including uptime guarantees, bears the risk of performance, and has discretion in establishing contract pricing. Accordingly, revenue is recognized on a gross basis.

 

Contract Balances and Remaining Performance Obligations

 

The Company’s contract liabilities consist of deferred revenue related to maintenance contracts billed in advance and customer deposits on pending equipment sales. These amounts are presented as deferred revenue on the accompanying balance sheets. There were no contract assets as of September 30, 2026 or December 31, 2025.

 

The Company has elected the practical expedient under ASC 606-10-50-14 not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for contracts with an original expected duration of one year or less.

 

F-22

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

Disaggregation of Revenue

 

The following table presents the Company’s revenues disaggregated by type for the three and nine months ended September 30, 2026 and 2025:

 

   Three Months Ended September 30, 
   2026   2025 
                 
Sales  Revenue   % of Revenues   Revenue   % of Revenues 
                     
Service Income  $102,667    100%  $111,000    100%
Total Revenues  $102,667    100%  $111,000    100%

 

   Nine Months Ended September 30, 
   2026   2025 
                 
Sales  Revenue   % of Revenues   Revenue   % of Revenues 
                     
Service Income  $325,489    100%  $350,452    100%
Total Revenues  $325,489    100%  $350,452    100%

 

All revenue recognized in both periods was derived from maintenance service contracts. No equipment sale revenue has been recognized in either period, as transfer of control of the equipment to the customer had not yet occurred as of each respective balance sheet date.

 

Deferred Revenue (Contract Liabilities)

 

Deferred revenue represents consideration received from customers prior to the satisfaction of the related performance obligation.

 

At September 30, 2026 and December 31, 2025, deferred revenue consisted of the following:

 

Type  September 30, 2026   December 31, 2025 
Customer deposit - equipment sale  $210,000   $70,000 
Customer deposit - other   -    50,000 
Total deferred revenue  $210,000   $120,000 

 

Equipment sale deposits represent cumulative installment payments received from customers under executed purchase agreements for medical scanning equipment. Title and physical possession of the equipment transfer to each customer upon receipt of the full

 

F-23

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

contract price, at which point revenue is recognized. During 2026, additional installment payments of $140,000 were received, bringing the aggregate cumulative balance to $210,000 at September 30, 2026.

 

The $50,000 balance at December 31, 2025 represented a payment received from a potential customer. This deposit was refunded in full during 2026. None of the deferred revenue at December 31, 2025 was recognized as revenue during 2026.

 

Maintenance contract amounts represent consideration received from customers prior to the applicable service period and are recognized as revenue ratably as performance obligations are satisfied over the service term. No maintenance contract amounts were deferred at September 30, 2026 or December 31, 2025.

 

Cost of Sales

 

Cost of sales consists of direct expenses incurred in the delivery of services related to the Company’s maintenance contracts. These costs are recognized as incurred and are directly attributable to fulfilling service obligations under customer agreements. Cost of sales also includes write-downs of inventory to net realizable value, including additional equipment costs incurred to ready inventory for sale.

 

The primary components of cost of sales include:

 

●Salaries and Wages – Compensation, payroll taxes, and employee benefits associated with the Company’s service technicians and clinical support staff.

●Job-Related Materials and Supplies – Expenses for parts, tools, software upgrades, and consumable materials required to perform maintenance and repairs.

 

All other costs included in cost of sales are directly related to the provision of contracted maintenance services and align with revenue recognition principles under FASB ASC 606.

 

The Company continually evaluates its cost structure to optimize service delivery while maintaining contractual uptime guarantees and quality assurance standards.

 

Income Taxes

 

The Company accounts for income taxes using the asset and liability method prescribed by FASB ASC 740, “Income Taxes”. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences of differences between the financial reporting and tax bases of assets and liabilities. These amounts are measured using enacted tax rates expected to apply in the periods when temporary differences reverse.

 

The effect of a change in tax rates on deferred tax balances is recognized as income or expense in the period that includes the enactment date.

F-24

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

 SEPTEMBER 30, 2026 AND 2025

 (UNAUDITED)  

 

Uncertain Tax Positions

 

The Company evaluates uncertain tax positions which requires that a tax position be recognized in the financial statements only if it is more likely than not (greater than 50% likelihood) to be sustained upon examination by tax authorities.

 

As of September 30, 2026 and December 31, 2025, the Company had no uncertain tax positions that qualified for recognition or disclosure in the financial statements.

 

The Company also recognizes interest and penalties related to uncertain tax positions in other expense in the Statement of Operations. No interest and penalties were recorded for the nine months ended September 30, 2026 and 2025.

 

Valuation of Deferred Tax Assets

 

The Company’s deferred tax assets include certain future tax benefits, such as net operating losses (NOLs), tax credits, and deductible temporary differences. A valuation allowance is required if it is more likely than not that some portion, or all, of the deferred tax assets will not be realized.

 

The Company reviews the realizability of deferred tax assets on a quarterly basis, or more frequently if circumstances warrant, considering both positive and negative evidence.

 

Considered in Valuation Allowance Assessment

 

The Company evaluates multiple factors in determining whether a valuation allowance is necessary, including:

 

●Historical earnings trends (cumulative pre-tax income or losses in the most recent three-year period)

●Future financial projections, including expected taxable income based on long-term estimates of business performance and market conditions

●Statutory carryforward periods for net operating losses and other deferred tax assets

●Prudent and feasible tax planning strategies that could impact the realization of deferred tax assets

●Nature and predictability of temporary differences and the timing of their reversal

●Sensitivity of financial forecasts to external factors such as commodity prices, market demand, and operational risks

 

While cumulative three-year losses are a strong indicator that a valuation allowance may be needed, a valuation allowance determination is not solely based on past losses—all available positive and negative evidence must be considered.

 

F-25

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

Valuation Allowance Determination

 

At September 30, 2026 and December 31, 2025, the Company recorded a full valuation allowance against its deferred tax assets, resulting in a net carrying amount of $0. This determination was based on cumulative losses in recent years and the lack of sufficient positive evidence to support the realization of deferred tax assets in the near term.

 

The Company will continue to evaluate its valuation allowance each reporting period and will recognize deferred tax assets in the future if sufficient positive evidence emerges to support their realization.

 

There was no income tax provision recorded for the nine months ended September 30, 2026 and 2025, as the Company incurred losses in both periods and maintains a full valuation allowance against its deferred tax assets.

 

Advertising Costs

 

Advertising costs are expensed as incurred. These costs are recognized as operating expenses in the period in which they are incurred and are classified within general and administrative expenses in the statements of operations.

 

The Company does not capitalize direct-response advertising costs, as they do not meet the criteria for deferral.

 

The Company recognized marketing and advertising costs as follows:

 

Three Months Ended September 30, 
2026   2025 
$71,192   $64,408 
        
Nine Months Ended September 30, 
2026   2025 
$236,112   $189,193 

 

Stock-Based Compensation

 

The Company accounts for stock-based compensation in accordance with ASC 718, Compensation - Stock Compensation. Compensation cost is measured at the grant-date fair value of the award and is recognized over the requisite service period (generally the vesting period) on a straight-line basis.

 

F-26

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

The guidance applies to share-based payment awards granted to both employees and non-employees. Pursuant to ASU 2018-07, Improvements to Nonemployee Share-Based Payment Accounting, awards granted to non-employees are accounted for in substantially the same manner as awards granted to employees, with fair value determined on the grant date.

 

The Company estimates the fair value of stock options granted using the Black-Scholes option-pricing model. The model incorporates the following key assumptions:

 

●Expected dividend yield - Based on the Company’s anticipated dividend policy over the expected life of the option (generally assumed to be zero, as the Company does not currently pay dividends).

●Expected volatility - Based on the historical volatility of the Company.

●Risk-free interest rate - Based on the yield on U.S. Treasury securities with maturities approximating the expected term of the option.

●Expected term - Estimated based on historical exercise behavior, contractual terms, and the simplified method (average of contractual term and vesting period) where appropriate.

 

The Company has elected the practical expedient under ASU 2016-09 to account for forfeitures as they occur rather than estimating them in advance. This election is applied consistently to all stock-based awards.

 

Stock-based compensation expense is classified in the statements of operations as a component of general and administrative expenses.

 

In addition, the Company applies the provisions of ASU 2016-09 related to the recognition of all excess tax benefits and tax deficiencies in income tax expense in the period in which they occur and the classification of cash paid for tax withholdings on behalf of employees as financing activities in the statement of cash flows.

 

Stock Warrants

 

In connection with certain financing transactions (debt or equity), consulting arrangements, or strategic partnerships, the Company may issue warrants to purchase shares of its common stock. Warrants that do not meet liability classification under ASC 480, “Distinguishing Liabilities from Equity”, are evaluated under ASC 815-40, “Contracts in Entity’s Own Equity”. The Company’s outstanding warrants are not puttable or mandatorily redeemable, do not require net cash settlement, and are indexed to the Company’s own common stock. Accordingly, they are classified as equity instruments in additional paid-in capital.

 

The fair value of warrants issued for compensation purposes is measured using the Black-Scholes option pricing model.

F-27

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

 SEPTEMBER 30, 2026 AND 2025

 (UNAUDITED)  

 

Accounting Treatment of Warrants

 

●Warrants issued in conjunction with common stock issuance are initially recorded at fair value as a reduction in Additional Paid-In Capital (APIC).

●Warrants issued for services are recorded at fair value and expensed over the requisite service period or immediately upon issuance if no service period exists.

●Warrants classified as liabilities due to settlement features or pricing adjustments are remeasured at fair value each reporting period, with changes recognized in earnings.

 

Basic and Diluted Earnings (Loss) per Share

 

The Company computes net loss per share in accordance with ASC 260, “Earnings Per Share.” Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period.

 

During all periods presented, the Company reported a net loss. Accordingly, all potentially dilutive common stock equivalents were excluded from the computation of diluted net loss per share because their inclusion would have been anti-dilutive. As a result, diluted net loss per share is equal to basic net loss per share for all periods presented.

 

The following potentially dilutive equity securities outstanding as of September 30, 2026 and 2025 were as follows:

 

   September 30, 2026   September 30, 2025 
Stock Options   5,150,000    - 
Warrants   2,530,000    2,100,000 
Series A, convertible preferred stock   -    1,088 
Series B, convertible preferred stock   -    48,000 
Total common stock equivalents   7,680,000    2,149,088 

 

Based on the potential common stock equivalents noted above at September 30, 2026, the Company has sufficient authorized shares of common stock (100,000,000) to settle any potential exercises of common stock equivalents.

 

Preferred Stock Classification

 

The Company applies the guidance outlined in ASC 480, “Distinguishing Liabilities from Equity”, in determining the appropriate classification and measurement of preferred stock. Under FASB ASC 480-10-25-4, financial instruments that embody an obligation to repurchase equity shares or require mandatory redemption at a fixed or determinable date must be classified as a liability and measured at fair value.

F-28

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

Preferred shares that are conditionally redeemable - including those redeemable at the option of the holder or subject to redemption upon the occurrence of events outside the issuer’s control - are classified as temporary equity in accordance with FASB ASC 480-10-S99-3A. Conversely, preferred shares that are not mandatorily redeemable and whose redemption rights are within the issuer’s control are appropriately classified as a component of stockholders’ equity.

 

Related Parties

 

The Company defines related parties in accordance with FASB ASC 850, “Related Party Disclosures,” and SEC Regulation S-X, Rule 4-08(k). Related parties include entities and individuals that, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company.

 

Related parties include, but are not limited to:

 

●Principal owners of the Company.

●Members of management (including directors, executive officers, and key employees).

●Immediate family members of principal owners and members of management.

●Entities affiliated with principal owners or management through direct or indirect ownership.

●Entities with which the Company has significant transactions, where one party has the ability to exercise control or significant influence over the management or operating policies of the other.

 

A party is considered related if it has the ability to control or significantly influence the management or operating policies of the Company in a manner that could prevent either party from fully pursuing its own separate economic interests.

 

The Company discloses all material related party transactions, including:

 

●The nature of the relationship between the parties.

●A description of the transaction(s), including terms and amounts involved.

●Any amounts due to or from related parties as of the reporting date.

●Any other elements necessary for a clear understanding of the transactions’ effects on the financial statements.

 

Disclosures are made in accordance with FASB ASC 850-10-50-1 through 50-6 and SEC Regulation S-X, Rule 4-08(k), which requires registrants to disclose material related party transactions and their effects on the financial position and results of operations.

 

F-29

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

See Note 5 for related party debt.

 

See Note 6 for operating lease.

 

See Note 9 for warrants.

 

Recent Accounting Standards

 

Recently Adopted Accounting Standards

 

FASB ASU 2023-07 - Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures

 

In November 2023, the FASB issued ASU 2023-07, which enhances reportable segment disclosure requirements by:

 

●Requiring disclosure of significant segment expenses regularly provided to the chief operating decision maker (CODM);

●Requiring disclosure of the title and position of the CODM;

●Extending certain annual disclosures to interim periods; and

●Clarifying that single reportable segment entities must apply ASC 280 in its entirety.

 

ASU 2023-07 is effective for annual periods beginning after December 15, 2023, and interim periods beginning after December 15, 2024, with retrospective application required.

 

The Company adopted ASU 2023-07 for its annual reporting period ended December 31, 2024, and for interim periods beginning January 1, 2025. The adoption resulted in enhanced segment disclosures but did not have a material impact on the Company’s financial position, results of operations, or cash flows.

 

FASB ASU 2023-09 - Income Taxes (Topic 740): Improvements to Income Tax Disclosures

 

In December 2023, the FASB issued ASU 2023-09, which enhances income tax disclosure requirements by:

 

●Standardizing and disaggregating rate reconciliation categories; and

●Requiring disclosure of income taxes paid by jurisdiction.

 

ASU 2023-09 is effective for annual periods beginning after December 15, 2024, and may be applied on a prospective or retrospective basis.

 

F-30

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

 SEPTEMBER 30, 2026 AND 2025

 (UNAUDITED)  

 

The Company adopted ASU 2023-09 effective January 1, 2025. The adoption resulted in enhanced income tax disclosures but did not have a material impact on the Company’s financial position, results of operations, or cash flows.

 

FASB ASU 2025-05 - Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets

 

In July 2025, the FASB issued ASU 2025-05, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. The ASU provides a practical expedient that permits entities to assume that current economic conditions as of the balance sheet date will remain unchanged over the remaining life of current (short-term) accounts receivable and current contract assets arising from transactions accounted for under ASC 606.

 

ASU 2025-05 is effective for fiscal years beginning after December 15, 2025, and interim periods within those fiscal years, with early adoption permitted in both interim and annual reporting periods in which financial statements have not yet been issued or made available for issuance. The amendments are required to be applied prospectively.

 

The Company early adopted ASU 2025-05 effective January 1, 2025 and elected the practical expedient. The adoption did not have a material impact on the Company’s financial position, results of operations, or cash flows.

 

FASB ASU 2024-04 - Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments

 

In November 2024, the FASB issued ASU 2024-04, which clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. The amendments also clarify that the incorporation, elimination, or modification of a volume-weighted average price (VWAP) formula does not automatically result in an extinguishment.

 

ASU 2024-04 is effective for annual periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. Adoption may be applied on a prospective or retrospective basis.

 

The Company adopted ASU 2024-04 effective January 1, 2026. The adoption did not have a material impact on the Company’s financial position, results of operations, or cash flows.

 

F-31

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

Recently Issued Accounting Standards Not Yet Adopted

 

FASB ASU 2024-03 / ASU 2025-01 - Income Statement (Topic 220): Reporting Comprehensive Income - Expense Disaggregation Disclosures

 

In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses, which requires public business entities to disclose, in annual and interim reporting periods, disaggregated information about certain income statement expense line items in a tabular format, along with a qualitative reconciliation to the captions on the face of the financial statements. In January 2025, the FASB issued ASU 2025-01 to clarify that the effective date for non-calendar year-end entities requires initial adoption in an annual reporting period, not an interim period.

 

The ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted and may be applied on either a prospective or retrospective basis. The Company is currently assessing the potential impact of ASU 2024-03 / ASU 2025-01 on its financial statement disclosures.

 

Other Accounting Standards Updates

 

The Company has evaluated all other recently issued accounting standards not yet effective and has determined that the adoption of such standards is not expected to have a material impact on the Company’s financial statements or disclosures. The FASB has also issued various technical corrections and industry-specific updates that are not expected to have a material impact on the Company’s financial position, results of operations, or cash flows.

 

Note 3 – Property and Equipment

 

Property and equipment consisted of the following:

 

   September 30, 2026   December 31, 2025   Estimated Useful
Lives (Years)
 
                
Equipment  $227,856   $227,856    5 
Accumulated depreciation   (150,530)   (122,104)     
Total property and equipment - net  $77,326   $105,752      

 

F-32

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

Depreciation Expense

 

Three Months Ended September 30, 
2026   2025 
$9,224   $8,476 
        
Nine Months Ended September 30, 
2026   2025 
$28,426   $17,776 

 

Note 4 – Convertible Advance Payable

 

The Company’s advances payable are as follows:

Terms  Convertible Advance Payable 
     
Issuance date of advances   Prior to 2018 
Maturity date   Due on Demand  
Interest rate   0% 
Collateral   Unsecured 
Conversion feature   45% discount to market price 
      
December 31, 2024  $563,000 
No activity in 2025   - 
December 31, 2025   563,000 
No activity in 2026   - 
September 30, 2026  $563,000 

 

The Company has a $310,000 advance payable to a former Chief Financial Officer of the Company. The advance was originally issued with no formal terms. Pursuant to a prior settlement, the creditor holds the option of repayment in either cash or shares of the Company’s common stock, at a 45% discount to the current market price of the common stock.

 

The Company has accounted for the advance payable under FASB ASC 480-10-25-14, given the obligation to issue a variable number of shares based solely or predominately on a fixed monetary amount, and recorded the liability at its fixed monetary amount of $563,000 representing the holder’s discount to market on its common shares expected upon settlement.

 

F-33

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

Note 5 – Debt

 

Notes Payable - Related Parties

 

The Company has entered into several notes payable with related parties, each of whom is a member of the Board of Directors, an entity affiliated with a member of the Board of Directors, or a significant stockholder.

 

A summary of notes payable - related parties as of September 30, 2026 and December 31, 2025 is as follows:

 

Terms     Note Payable #1
Related Party
      Note Payable #2
Related Party
      Note Payable #3
Related Party
      Note Payable #4
Related Party
      Note Payable #5
Related Party
      Note Payable #6
Related Party
         
Issuance dates of notes     August 2022       April 2023       August 2024       February 2025       September 2026       September 2026          
Maturity date     December 2026       March 2025       December 2024       March 2025       September 2027       September 2027          
Interest rate     10%       8%       0%       0%       20%       20%          
Imputed interest rate     N/A       N/A       8%       8%       N/A       N/A          
Default interest rate     20%       20%       20%       None       None       None          
Collateral     PET-CT Imaging Device       PET-CT Imaging Device       PET-CT Imaging Device       Unsecured       Unsecured       Unsecured          
                                                         
                           Total 
December 31, 2024  $1,200,000   $150,000   $100,000   $-   $-   $-   $1,450,000 
Proceeds from issuance of note   -    -    -    100,000    -    -    100,000 
Repayments   -    (150,000)   (100,000)   (100,000)   -    -    (350,000)
December 31, 2025   1,200,000    -    -    -    -    -    1,200,000 
Repayments   (325,000)   -    -    -    -    -    (325,000)
Proceeds from issuance of note   -    -    -    -    1,500,000    400,000    1,900,000 
Debt discount (300,000 warrants)   -    -    -    -    (325,602)   -    (325,602)
Debt discount (80,000 warrants)   -    -    -    -    -    (86,827)   (86,827)
September 30, 2026  $875,000   $-   $-   $-   $1,174,398   $313,173   $2,362,571 

 

Note #1

 

Note #1 is held by an entity affiliated with a member of the Board of Directors.

 

In March 2025, Note #1 was extended to December 31, 2025.

 

On February 16, 2026, Note #1 was further extended to June 30, 2026.

 

On June 30, 2026, Note #1 was further extended to December 31, 2026. 

F-34

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

The Company evaluated each extension under FASB ASC 470-50-40 and concluded that the extensions did not constitute a substantive modification. Accordingly, no debt extinguishment occurred and no gain or loss was recognized.

 

Note #1 is collateralized by the Company’s sole imaging device, which is carried in inventory.

 

The lender has authorized the sale of the collateral, and the loan agreement requires sale proceeds to be applied toward the outstanding loan balance.

 

During the nine months ended September 30, 2026, the Company repaid $325,000.

 

Accrued interest payable of $474,236 and $407,017 on Note #1 was included as a component of accounts payable and accrued expenses – related parties in the accompanying balance sheets at September 30, 2026 and December 31, 2025.

  

Note #2

 

In April 2023, the Company executed a one-year note with a shareholder and director in the principal amount of $500,000. The note bears interest at 8.0% per annum, with a default rate of 20.0%, and is secured by the net proceeds from the Company’s PET imaging devices and service contracts. Original principal was payable 50% on December 31, 2023 and 50% plus accrued interest on March 31, 2024.

 

The note was extended and repaid in full as follows:

 

●In March 2024, the remaining balance of $250,000 was extended to September 2024. During 2024, $100,000 of principal was repaid.

●In September 2024, the remaining balance of $150,000 was extended to March 2025.

●During 2025, the remaining $150,000 of principal was repaid in full, and $41,414 of accrued interest was forgiven by the lender.

 

Because the lender is a significant stockholder and director, the Company accounted for the interest forgiveness as a capital contribution, recording $41,414 as an increase to additional paid-in capital rather than as a gain on extinguishment. This treatment is consistent with FASB ASC 470-50-40-2, which addresses extinguishment transactions between related parties, and with FASB ASC 850-10-50-5, which requires related-party transactions to be presented in accordance with their substance rather than as arm’s length transactions.

 

The Company evaluated the 2024 and 2025 extensions under FASB ASC 470-50-40 and concluded that the extensions did not add or eliminate a substantive conversion feature, did not result in cash flows that differed by 10% or more from those under the original instrument, and did not result in significant changes to interest rate, collateral, or repayment terms beyond the extension of maturity. Accordingly, no debt extinguishment occurred and no gain or loss was recognized.

 

In connection with the original issuance of the note in 2023, the Company issued 100,000 warrants to the lender with an exercise price of $0.10 per share. The warrants vested

 

F-35

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

immediately and had an original expiration date of December 31, 2025. The fair value of the warrants of $126,699 was recorded as a debt discount and amortized over the original term of the note. On December 31, 2025, the expiration date of the warrants was extended to December 31, 2026, with no financial statement impact (see Note 9).

 

Note #3

 

In August 2024, the Company executed a four-month, non-interest-bearing note with a shareholder and director in the principal amount of $100,000, with a default interest rate of 20%. The note was secured by the net proceeds from the Company’s PET imaging devices and service contracts. Because the note was issued by a related party at a below-market interest rate, the Company recorded imputed interest at 8%, resulting in interest expense of $1,600 for the year ended December 31, 2024, with a corresponding credit to additional paid-in capital. The note was repaid in full in March 2025.

 

Note #4

 

In February 2025, the Company executed a one-month, non-interest-bearing, unsecured note with a shareholder and director in the principal amount of $100,000. The Company recorded imputed interest at 8%, resulting in interest expense of $1,336 for the year ended December 31, 2025, with a corresponding credit to additional paid-in capital. The note was repaid in full during 2025.

 

Notes #5 and #6

 

On September 30, 2026, the Company issued two unsecured promissory notes to two related parties in the aggregate principal amount of $1,900,000, as follows:

 

●Note #5: $1,500,000, issued to a significant stockholder of the Company, who is also the lender under the line of credit described below.

●Note #6: $400,000, issued to an entity affiliated with a member of the Board of Directors, which is also the holder of Note #1.

 

Each note was issued September 30, 2026 and matures September 30, 2027, bears interest at 20% per annum, and requires an interim interest payment equal to 10% of the original principal on March 30, 2027 ($150,000 and $40,000, respectively), with the remaining accrued interest due at maturity or earlier repayment. The notes may be prepaid at any time without penalty. Events of default are limited to nonpayment and bankruptcy, and the notes carry no default interest rate.

 

As additional consideration, the Company issued to the lenders warrants to purchase 300,000 shares (Note #5) and 80,000 shares (Note #6) of common stock at an exercise price of $2/share, expiring December 31, 2030. The warrants are freestanding instruments

 

F-36

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

indexed to the Company’s own common stock and are classified in equity under ASC 815-40. Proceeds were allocated between the notes and the warrants on a relative fair value basis under ASC 470-20-25-2, resulting in a debt discount of $412,429, which is amortized to interest expense over the term of the notes on a straight-line basis, which is not materially different from the interest method. At September 30, 2026, the unamortized debt discount was $412,429; the notes, net of the discount, are classified as current liabilities because they mature within twelve (12) months of the balance sheet date (see Note 9).

 

Line of Credit - Related Party

 

On August 13, 2026, the Company entered into a $2,000,000 revolving line of credit with a significant stockholder of the Company (the “Related Party Lender”), maturing August 13, 2028.

 

Advances bear interest at 12% per annum, payable quarterly in arrears, with principal payable from August 13, 2027 through maturity.

 

Advances may be prepaid without penalty and reborrowed. The line of credit is unsecured.

 

Advances are subject to the following limitations:

 

●$500,000 maximum per calendar quarter.

●$100,000 minimum per advance.

●Fourteen (14) days written notice per advance.

 

Proceeds are restricted to working capital, commercialization of the Company’s PET-CT imaging platform, customer installations, inventory and growth initiatives. Without the lender’s consent, the Company may not:

 

(i)liquidate or dissolve;

(ii)merge or consolidate; or

(iii)dispose of substantially all of its assets.

 

Events of default include:

 

●Nonpayment of interest, after a ten (10) business day cure period.

●Nonpayment of principal.

●Material misrepresentation, or a covenant breach not cured within thirty (30) days.

●Insolvency, bankruptcy or receivership.

●A material adverse event.

F-37

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

Upon an event of default, the lender may accelerate all amounts due, and principal bears interest at 18% per annum. No advances had been drawn at September 30, 2026.

 

Warrants Issued in Connection with the Line of Credit

 

In consideration of the commitment, on August 13, 2026 the Company issued the Related Party Lender warrants to purchase 300,000 shares of common stock at an exercise price of $1.50/share, expiring December 31, 2030, which remain outstanding whether or not advances are made. The exercise price is reduced to $1/share upon an event of default. The warrants are indexed to the Company’s own common stock and are classified in equity.

 

The fair value of the warrants of $420,177 (see Note 9) was recorded as a deferred financing cost and is amortized on a straight-line basis over the twenty-four (24) month term of the line of credit, whether or not advances are outstanding. Amortization of $35,014 is included in interest expense - related parties for the three and nine months ended September 30, 2026.

 

Deferred financing costs - related party consisted of the following:

 

  September 30, 2026   December 31, 2025 
Fair value of warrants - deferred financing costs  $420,177   $- 
Less: amortization - deferred financing costs   35,014    - 
Unamortized deferred financing costs - net   385,163    - 
Less: short term   210,084    - 
Long-term  $175,079   $- 

 

Note 6 – Commitments and Contingencies

 

Operating Lease

 

The Company accounts for leases in accordance with FASB ASC 842: Leases, which requires lessees to apply the right-of-use (ROU) model by recognizing a right-of-use asset and a lease liability for all leases with terms exceeding 12 months.

 

Lease classification determines the pattern of expense recognition in the Statements of Operations:

 

●Operating leases: Recognized on a straight-line basis as lease expense over the lease term.

F-38

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

Lease Recognition and Measurement

 

The Company evaluates whether an arrangement contains a lease at inception and recognizes the lease in the financial statements upon lease commencement (the date the underlying asset is available for use). ROU assets represent the Company’s right to use an asset over the lease term, while lease liabilities reflect the present value of future lease payments.

 

At lease commencement:

 

●ROU assets and lease liabilities are initially measured at the present value of lease payments.

●The Company primarily uses its incremental borrowing rate (IBR) to determine the present value of lease payments, except when an implicit rate is readily determinable.

●The IBR is based on market data, adjusted for credit risk and lease term.

 

Practical Expedients and Lease Components

 

The Company applies certain practical expedients to simplify lease accounting:

 

●Lease and non-lease components are combined for classification and measurement, except for direct sales-type leases and production equipment embedded in supply agreements.

●Short-term leases (12 months or less, without purchase or renewal options) are not recorded on the balance sheet.

 

Lease Term and Expense Recognition

 

●Lease liabilities include options to extend or terminate when reasonably certain of exercise.

●Operating lease expense is recognized on a straight-line basis over the lease term and reported under general and administrative expenses.

●Variable lease payments based on an index/rate are initially measured using the rate at lease commencement, with differences expensed as incurred.

 

Company Lease Commitments

 

As of September 30, 2026 and December 31, 2025, the Company had no finance leases under FASB ASC 842.

F-39

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

 SEPTEMBER 30, 2026 AND 2025

 (UNAUDITED)  

 

Right-of-Use Operating Lease

 

On July 8, 2025, the Company executed a five-year lease for its office space, covering the period from July 8, 2025 to July 8, 2030.

 

See below regarding original lease and related termination of that lease.

 

●Lease term: 60 months (five years)

●Monthly lease payments:

○Months 1-12: $3,626 per month

○Months 13-24: $3,777 per month

○Months 25-60: $4,200 per month

●Total lease payments: $240,036 (excluding variable monthly operating expenses)

●Occupancy date: August 1, 2025

●Renewal option: The lease has no renewal options.

●Lease classification: The lease is evaluated under FASB ASC 842, Leases, and recorded as a right-of-use (ROU) asset and lease liability based on the present value of lease payments ($196,049) at lease commencement.

●Lease incentives/allowances – none

●Guarantee – The lease is guaranteed by the Company’s Chief Executive Officer. The guarantee is unconditional and continuing, and covers the full performance of the lease obligations, including payment of rent and fulfillment of all tenant responsibilities.

 

The Company recognizes lease expense on a straight-line basis over the lease term.

 

Right-of-Use Operating Lease – Lease Termination

 

On June 26, 2025, the Company entered into an agreement to terminate its existing operating lease (originally executed March 17, 2022), which was originally scheduled to expire on May 31, 2027. The last payment was made July 1, 2025. Pursuant to the agreement, the termination is effective as of August 31, 2025.

 

As part of the termination agreement, the Company paid a lump-sum settlement of $20,000 to the lessor. This payment has been recorded as a lease termination expense in the Statements of Operations in 2025.

 

Upon termination, the Company:

 

●Derecognized the right-of-use (ROU) asset and the corresponding lease liability related to the lease;

●Recognized any difference between the asset and liability as a gain or loss on lease termination;

F-40

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

●Included the $20,000 termination fee in the total expense recognized upon derecognition.

 

Loss on lease termination of $15,018 was calculated as follows:

      
Right-of-Use Asset  $28,228 
Cash paid to terminate lease   20,000 
Lease liability   (33,210)
Loss on lease termination  $15,018 

 

On March 17, 2022, the Company executed a five-year lease extension for its office space, covering the period from June 1, 2022, through May 31, 2027.

 

●Lease term: 60 months (five years)

●Monthly lease payments:

○Years 1-3: $1,600 per month

○Years 4-5: $1,700 per month

●Total lease payments: $57,600 for the first three years and $40,800 for the last two years

●Renewal option: The Company has the option to extend the lease for an additional five years through May 31, 2032.

●Lease classification: The lease is evaluated under FASB ASC 842, Leases, and recorded as a right-of-use (ROU) asset and lease liability based on the present value of lease payments at lease commencement.

●Renewal option assessment: At lease inception, based on historical operations, the Company does not expect to exercise the renewal option and has excluded it from lease liability calculations.

 

The Company recognizes lease expense on a straight-line basis over the lease term.

 

F-41

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

The tables below present information regarding the Company’s operating lease asset and liability at September 30, 2026 and December 31, 2025, respectively:

 

   September 30, 2026   December 31, 2025 
Assets        
         
Operating lease - right-of-use asset - non-current  $150,306   $179,711 
           
Liabilities          
           
Operating lease liability  $161,835   $184,298 
           
Weighted-average remaining lease term (years)   3.84    4.58 
           
Weighted-average discount rate   8%   8%
           

The components of lease expense were as follows for the nine months ended September 30:

 

   2026   2025 
           
Operating lease costs   -       
           
Amortization of right-of-use operating lease asset  $29,405   $17,283 
Lease liability expense in connection with obligation repayment   10,473    3,078 
Total operating lease costs  $39,878   $20,361 
           
Supplemental cash flow information related to operating leases was as follows:          
           
Operating cash outflows from operating lease (obligation payment)  $32,936   $20,352 
Right-of-use asset obtained in exchange for new operating lease liability  $-   $196,049 

 

F-42

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

Future minimum lease payments required under leases that have initial or remaining non-cancelable lease terms in excess of one year at September 30, 2026, by year ending December 31:

 

2026 (3 months)  $11,331 
2027   47,439 
2028   50,400 
2029   50,400 
Thereafter   29,400 
Total undiscounted cash flows   188,970 
Less: amount representing interest   27,135 
Present value of operating lease liability   161,835 
Less: current portion of operating lease liability   34,440 
Long-term operating lease liability  $127,395 

 

Contingencies – Strategic Cooperation Agreement

 

On January 15, 2022, the Company entered into a strategic cooperation agreement with a supplier for the development, manufacture, and distribution of PET/CT imaging systems. The agreement establishes transfer pricing terms for PET/CT systems that become effective only upon receipt of U.S. Food and Drug Administration (FDA) clearance for the Company’s next-generation PET/CT 4D system, which is currently undergoing testing in preparation for submission of a 510(k) amendment.

 

All obligations under the agreement are expressly conditioned upon receipt of FDA clearance, a future regulatory event outside the Company’s control. Following clearance, the agreement will have an initial term of seven years, which may be extended for an additional three years subject to the Company’s achievement of specified annual purchase requirements during the initial term.

 

The Company evaluated this arrangement under FASB ASC 440, Commitments, and concluded that it does not constitute an unconditional purchase obligation under ASC 440-10-50-2 because all purchase obligations are contingent upon receipt of FDA clearance. Accordingly, no disclosure of minimum future purchase commitments is required under ASC 440-10-50-4.

 

The Company further evaluated the arrangement under FASB ASC 450, Contingencies. As of September 30, 2026 and December 31, 2025, FDA 510(k) clearance remained subject to regulatory review. The Company believes the established 510(k) substantial equivalence pathway, supported by previously FDA-cleared predicate technology, provides a well-defined regulatory framework for obtaining clearance, and anticipates clearance within its projected timeframe. However, because the timing and ultimate determination remain subject to the FDA’s regulatory review process, receipt of FDA clearance is considered reasonably possible but not probable. Accordingly, no accrual has been recorded, and the financial impact of the arrangement, if any, cannot be reasonably estimated until FDA clearance is obtained. There can be no assurance that FDA clearance will be obtained within the anticipated timeframe or at all.

 

F-43

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

Contingencies – Legal Matters

 

The Company may be subject to litigation claims arising in the ordinary course of business. The Company records litigation accruals for legal matters which are both probable and estimable and for related legal costs as incurred. The Company does not reduce these liabilities for potential insurance or third-party recoveries.

 

As of September 30, 2026 and December 31, 2025, respectively, the Company is not aware of any litigation, pending litigation, or other transactions that require accrual or disclosure.

 

Note 7 – Stockholders’ Equity (Deficit)

 

The Company has two classes of capital stock: preferred stock and common stock.

 

Authorized Capital Structure

 

The Company is authorized to issue 110,000,000 shares of capital stock, consisting of 100,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share.

 

On October 27, 2025, the Company filed two Certificates of Amendment with the Texas Secretary of State, each effective as of that date:

 

●The first amendment reduced the authorized common stock from 6,000,000,000 shares to 100,000,000 shares, reduced the authorized preferred stock from 20,000,000 shares to 10,000,000 shares, and reduced the par value of the preferred stock from $1.00 per share to $0.0001 per share. The par value of the common stock was unchanged.

●The second amendment was a conforming amendment that restated the conversion provisions of the Series A Preferred Stock, including the anti-dilution adjustment formula, to align the Certificate of Formation with the conversion terms in effect since the original designation. The amendment did not modify the economic rights or preferences of the Series A Preferred Stock.

 

The board of directors is authorized, without further stockholder approval, to designate one or more series of preferred stock from time to time and to fix the rights, preferences, limitations, and restrictions of each series prior to issuance, including dividend rights, voting rights, redemption terms, conversion and exchange rights, liquidation preferences, and ranking among different series of preferred stock.

 

F-44

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

Preferred Stock - Series Designations

 

Effective March 18, 2026, the Company filed a Certificate of Amendment with the Texas Secretary of State undesignating all previously designated series of preferred stock. The following series were undesignated, and the underlying shares were returned to the authorized but unissued preferred stock pool:

 

●Series A: 5,450,000 shares

●Series B: 9,000,000 shares

●Series C: 840,000 shares

●Series D: 1,560,000 shares

●Series E: 1,200,000 shares

●Series F: 600,000 shares

●Series G: 3,000,000 shares

●Series H: 15,000,000 shares

●Series S: 100,000 shares

 

In the aggregate, 36,750,000 shares previously designated across these nine series were returned to the authorized but unissued preferred stock pool. As a result of the undesignation, no series of preferred stock are currently designated, and no shares of preferred stock were issued or outstanding at September 30, 2026. The board of directors retains the authority to designate new series of preferred stock from the authorized 10,000,000 share pool at a future date without further stockholder approval.

 

Series A Preferred Stock

 

Prior to its undesignation, the Company had designated 5,450,000 shares of Series A 8% Cumulative Convertible Redeemable Preferred Stock at $0.0001 par value per share. The material terms of the Series A Preferred Stock were as follows:

 

●Dividends. Holders were entitled to cumulative dividends at a rate of 8% per annum ($0.1064 per share per year), payable semi-annually on January 1 and July 1 of each year. Dividends were payable in cash or, at the Company’s election, in additional shares of Series A Preferred Stock valued at $1.33 per share.

●Liquidation Preference. Upon any liquidation, dissolution, or winding up of the Company, holders were entitled to receive $1.33 per share plus all accumulated and unpaid dividends, prior to any distribution to holders of any other series of preferred stock or common stock.

F-45

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

 SEPTEMBER 30, 2026 AND 2025

 (UNAUDITED)  

 

●Conversion. Each share of Series A Preferred Stock was convertible, at the option of either the Company or the holder, into common stock at a ratio of 1 share of common stock for every 400 shares of Series A Preferred Stock. The conversion ratio was subject to adjustment for stock splits, stock dividends, combinations, reclassifications, and below-market issuances pursuant to a broad-based weighted average anti-dilution formula.

●Redemption. The Company had the right to redeem the Series A Preferred Stock, in whole or in part, at any time after the second anniversary of the Final Closing Date (as defined in the Certificate of Formation) at a redemption price of $1.46 per share plus all accumulated and unpaid dividends, provided that the common stock had closed at or above $2.00 per share for 20 consecutive trading days prior to the redemption notice. The Company was required to provide 30 days’ prior written notice of any redemption.

●Voting Rights. Holders voted together with holders of common stock as a single class on all matters submitted to a vote of stockholders, with each holder entitled to cast one vote for each share of common stock into which such holder’s Series A Preferred Stock was then convertible.

 

Series B Preferred Stock

 

Prior to its undesignation, the Company had designated 9,000,000 shares of Series B Convertible Preferred Stock at $0.0001 par value per share. The material terms of the Series B Preferred Stock were as follows:

 

●Conversion. Series B Preferred Stock was convertible into common stock at a contractual ratio of 0.25 shares of common stock per share of Series B Preferred Stock surrendered, subject to adjustment for stock splits and combinations. The Certificate of Designation provided for a 125% conversion factor, resulting in an effective conversion ratio of 0.3125 shares of common stock per share of Series B Preferred Stock.

●Voting Rights. Holders were entitled to 100 votes per share on all matters submitted to a vote of stockholders, voting together with holders of common stock as a single class.

 

Conversion of Preferred Stock

 

On October 30, 2025, all 435,085 shares of Series A Preferred Stock and all 192,000 shares of Series B Preferred Stock then issued and outstanding were converted into common stock as follows:

 

●The 435,085 shares of Series A Preferred Stock were converted into 1,101 shares of common stock (which includes 13 inducement shares) at the contractual ratio of 1 share of common stock for every 400 shares of Series A Preferred Stock.

F-46

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

●The 192,000 shares of Series B Preferred Stock were converted into 60,009 shares of common stock at the contractual effective ratio of 0.3125 shares of common stock per share of Series B Preferred Stock.

 

Fractional shares resulting from each conversion were rounded up to the nearest whole share. Both conversions were accounted for as reclassifications within stockholders’ equity, with the carrying amount of the converted preferred stock reclassified to common stock and additional paid-in capital. No gain or loss was recognized.

 

Following the October 30, 2025 conversions, no shares of preferred stock of any series remained issued and outstanding at December 31, 2025 or September 30, 2026.

 

Common Stock

 

-100,000,000 shares authorized

-$0.0001 par value

-Voting at 1 vote per share

 

Equity Transactions for the Nine Months Ended September 30, 2026

 

Stock Issued for Services

 

The Company issued 50,000 shares of common stock to a consultant for services rendered, having a fair value of $94,500 ($1.89/share), based upon the quoted closing trading price on the grant date.

 

Cancellation of Shares

 

The Company cancelled 3,125 shares of common stock related to a prior period conversion of Series A Convertible Preferred Stock to common stock.

 

Exercise of Warrants

 

The Company issued 250,000 shares of common stock to a significant stockholder upon the exercise of previously issued warrants at an exercise price of $1/share, for proceeds of $250,000.

 

Warrants Issued

 

During the three months ended September 30, 2026, the Company issued 680,000 warrants to related parties in connection with a line of credit and notes payable (see Notes 5 and 9).

 

F-47

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

 SEPTEMBER 30, 2026 AND 2025

 (UNAUDITED)  

 

Equity Transactions for the Year Ended December 31, 2025

 

Stock Issued for Cash

 

The Company issued 9,333,333 shares of common stock for $10,000,000 ($1.00 - $1.50/share). Of the total shares issued, 8,000,000 were sold to a related party, who is a principal stockholder for $8,000,000.

 

Common Stock Repurchase Agreement

 

The Company repurchased 4,000,000 shares of common stock from a stockholder for $2,500,000 ($0.60 - $0.75/share).

 

The repurchased shares were cancelled and retired upon acquisition and are no longer considered issued or outstanding. In accordance with FASB ASC 505-30, “Equity – Treasury Stock”, and consistent with the Company’s corporate charter and applicable state law, the cancelled shares were returned to the status of authorized but unissued, thereby increasing the number of shares available for future issuance.

 

The repurchase was accounted for as a reduction to stockholders’ equity, with the purchase price allocated entirely to Additional Paid-in Capital (“APIC”), as the Company had sufficient APIC available from prior issuances. No gain or loss will be recognized in connection with this transaction. The cash outflow related to the stock repurchase will be classified as a financing activity in the statement of cash flow.

 

In conjunction with the stock repurchase, the Company also issued 500,000 freestanding warrants to the selling stockholder. The warrants have an exercise price of $1 and expire on December 31, 2026. The warrants were classified as equity instruments and recorded at fair value, with a corresponding credit to APIC. As the warrants were issued as part of the consideration for the share repurchase, their fair value was included in the total cost of the repurchase transaction, resulting in a net effect of $0 on total stockholders’ equity.

 

See Note 9 for warrants.

 

Stock Issued for Services

 

The Company issued 100,000 shares of common stock to a consultant for services rendered, having a fair value of $177,000 ($1.77/share), based upon the quoted closing trading price on the grant date.

 

F-48

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

Note 8 - Stock Option Plan

 

In May 2021, the Company adopted an equity incentive plan (the “Plan”). Under the Plan, the Company may grant up to 10,000,000 stock options to eligible participants. All terms for stock options granted under the Plan will be set by the Board of Directors.

 

Stock Option Grants

 

On November 5, 2025, the Company granted stock options to certain executives and employees to purchase an aggregate of 5,150,000 shares of the Company’s common stock at an exercise price of $1.48 per share. The options have a contractual term of five (5) years and were fully vested on the grant date. The grant was approved by the Board of Directors and was made pursuant to the Plan. After giving effect to the November 5, 2025 grant, 4,850,000 shares remained available for future issuance under the Plan at both September 30, 2026 and December 31, 2025.

 

Of the total grant, 1,500,000 options were granted to the Company’s Chairman of the Board of Directors and President and 750,000 options were granted each to a member of the Board of Directors and the Company’s Vice-President.

 

The aggregate grant date fair value of stock options granted during the year ended December 31, 2025 was $4,982,588. The weighted average grant date fair value per option was $0.97.

 

Valuation Methodology and Assumptions

 

The fair value of stock options granted was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:

 

Exercise price  $1.48 
Expected term   2.5 years 
Expected volatility   115%
Expected dividends   0%
Risk free interest rate   3.63%

 

F-49

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

Stock Option activity for the nine months ended September 30, 2026 and the year ended December 31, 2025 are summarized as follows:

 

Stock Options  Number of
Options
   Weighted
Average
Exercise Price
   Weighted
Average
Remaining
Contractual
Term (Years)
  

Aggregate
Intrinsic
 

Value 

  

Weighted
Average
Grant
Date 

Fair Value 

 
Outstanding - December 31, 2024  -                 
Exercisable - December 31, 2024  -                 
Granted   5,150,000   $1.48    4.85        $0.97 
Exercised   -                     
Cancelled/Forfeited   -                     
Outstanding - December 31, 2025   5,150,000   $1.48    4.85   $-      
Exercisable - December 31, 2025   5,150,000   $1.48    4.85   $-      
Granted   -   $-                
Exercised   -                     
Cancelled/Forfeited   -                     
Outstanding - September 30, 2026   5,150,000   $1.48    4.10   $1,586,200      
Exercisable - September 30, 2026   5,150,000   $1.48    4.10   $1,586,200      

 

Compensation Expense

 

The Company recognized stock-based compensation expense of $4,982,588 related to stock options for the year ended December 31, 2025, which was included in general and administrative expenses in those statements of operations. As the options were fully vested on the grant date, there was no unrecognized compensation cost related to stock options as of December 31, 2025 or September 30, 2026.

 

F-50

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

Note 9 – Warrants

 

Warrant activity for the nine months ended September 30, 2026 and the year ended December 31, 2025 are summarized as follows:

 

Warrants   Number of
Warrants
   Weighted
Average
Exercise Price
   Weighted
Average
Remaining
Contractual
Term (Years)
   Aggregate
Intrinsic
Value
 
Outstanding - December 31, 2024   1,600,000   $0.24    1.63   $1,231,000 
Exercisable - December 31, 2024   1,600,000   $0.24    1.63   $1,231,000 
Granted   500,000   $1.00           
Exercised   -                
Cancelled/Forfeited   -                
Outstanding - December 31, 2025   2,100,000   $0.42    1.00   $2,622,000 
Exercisable - December 31, 2025   2,100,000   $0.42    1.00   $2,622,000 
Granted   680,000   $1.78           
Exercised   (250,000)  $1.00           
Cancelled/Forfeited   -                
Outstanding - September 30, 2026   2,530,000   $0.73    1.33   $2,759,200 
Exercisable - September 30, 2026   2,530,000   $0.73    1.33   $2,759,200 

 

In December 2024, the Company extended the maturity dates of 1,000,000 warrants from December 31, 2024 to December 31, 2026. The value resulting from this modification was not considered material to the financial statements.

 

In December 2025, the Company extended the maturity dates of 600,000 warrants from December 31, 2025 to December 31, 2026. The value resulting from this modification was not considered material to the financial statements.

 

During the nine months ended September 30, 2026, the Company issued the following warrants to related parties:

 

●300,000 warrants at an exercise price of $1.50/share, expiring December 31, 2030, issued August 13, 2026 to a significant stockholder in consideration of a line of credit commitment (see Note 5).

●300,000 warrants at an exercise price of $2/share, expiring December 31, 2030, issued September 30, 2026 to a significant stockholder with Note #5 (see Note 5).

●80,000 warrants at an exercise price of $2/share, expiring December 31, 2030, issued September 30, 2026 to an entity affiliated with a member of the Board of Directors with Note #6 (see Note 5).

F-51

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

Valuation Methodology and Assumptions

 

The fair value of the warrants issued during the nine months ended September 30, 2026 was estimated on the date of grant using the Black-Scholes-Merton option pricing model with the following assumptions:

 

  

Line of Credit Warrants 

August 13, 2026

  

Notes #5 and #6
Warrants 
September 30, 2026 

 
           
Number of warrants   300,000    380,000 
Stock price on the grant date  $1.74   $1.788 
Exercise price  $1.50   $2.00 
Expected term (years)   4.38    4.25 
Expected volatility   114.2%   114.8%
Expected dividends   0.0%   0.0%
Risk-free interest rate   4.28%   5.06%
Fair value per warrant  $1.4006   $1.3863 
Aggregate fair value  $420,177   $526,775 

 

The fair value of the 300,000 warrants issued with the line of credit ($420,177) was recorded as a deferred financing cost asset (see Note 5). The fair value of the 380,000 warrants issued with Notes #5 and #6 was allocated on a relative fair value basis, and $412,429 was recorded as a debt discount (see Note 5).

 

On September 2, 2026, 250,000 warrants were exercised at an exercise price of $1/share (see Note 7).

 

Note 10 – Subsequent Events

 

The Company had the following subsequent events after September 30, 2026.

 

Exercise of Warrants

 

On September 26, 2026, a significant stockholder delivered notice to exercise the 300,000 warrants issued in connection with the line of credit at an exercise price of $1.50/share. The aggregate exercise price of $450,000 is payable upon exercise, and the shares will be issued upon receipt of payment. As of the date of these financial statements, payment had not been received and no shares had been issued.

F-52

 

 

POSITRON CORPORATION

NOTES TO FINANCIAL STATEMENTS

 SEPTEMBER 30, 2026 AND 2025

 (UNAUDITED)  

 

Note Payable

 

The Company received proceeds of $100,000 from an unsecured promissory note issued to an individual lender on the same terms as Notes #5 and #6: interest at 20% per annum, an interim interest payment equal to 10% of the original principal on March 30, 2027, and maturity on September 30, 2027 (see Note 5). In connection with the note, the Company agreed to issue the lender warrants to purchase 20,000 shares of common stock at an exercise price of $2/share, expiring December 31, 2030.

 

F-53

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Information Regarding and Factors Affecting Forward Looking Statements

 

The Company is including the following cautionary statement in this Quarterly Report on Form 10-Q to make applicable and take advantage of the safe harbor provision of the Private Securities Litigation Reform Act of 1995 for any forward looking statements made by, or on behalf of the Company. Forward looking statements include statements concerning plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements which are other than statements of historical facts. Certain statements contained herein are forward looking statements and, accordingly, involve risks and uncertainties which could cause actual results or outcomes to differ materially from those expressed in the forward looking statements.

 

The Company’s expectations, beliefs and projections are expressed in good faith and are believed by the Company to have a reasonable basis, including without limitations, management’s examination of historical operating trends, data contained in the Company’s records and other data available from third parties, but there can be no assurance that management’s expectations, beliefs or projections will result or be achieved or accomplished. In addition to other factors and matters discussed elsewhere herein, the following are important factors that, in the view of the Company, could cause actual results to differ materially from those discussed in the forward looking statements: the ability of the Company to attain widespread market acceptance of its systems; the ability of the Company to obtain acceptable forms and amounts of financing to fund future operations; demand for the Company’s services; and competitive factors. The Company disclaims any obligation to update any forward looking statements to reflect events or circumstances after the date hereof.

 

General Overview

 

Organization

 

Positron Corporation (the “Company” or “Positron”) was incorporated under the laws of the State of Texas in 1983. Unless the context requires otherwise, in this report the terms “we,” “us”, “our”, “the Company”, and “Positron” refer to Positron Corporation.

 

Corporate History

 

Positron Corporation was incorporated as a Texas corporation in 1983 with its corporate headquarters in North Tonawanda, New York.

 

Nature of Business. Positron is a medical technology company that co-develops, manufactures and sells PET and PET-CT imaging systems, delivering high-performance, cost-effective molecular imaging solutions that empower healthcare providers to improve the diagnosis and treatment of cardiovascular disease and other critical conditions. By combining proprietary PET and PET-CT systems with comprehensive clinical and technical support, flexible financing, and a focus on operational efficiency, Positron makes advanced diagnostic imaging more accessible and sustainable for hospitals, outpatient centers, and physician practices.

 

With a specialization in cardiac PET imaging and a growing presence in oncology and neurology, Positron stands at the forefront of innovation in nuclear medicine. Its systems are designed to enhance patient outcomes, maximize system uptime, and reduce total cost of ownership-offering unmatched clinical value and economic advantage in today’s healthcare environment.

 

4

 

 

In 2023, the Company entered an expanded business cooperation / OEM Supply and Distribution / SKD Manufacturer Agreement with Shenyang Intelligent Nuclear Medical Technology Co. a subsidiary of Neusoft Medical Systems, which secured exclusive rights for the North American market to sell/distribute PET, PET-CT and next generation PET-CT scanners in the future.

 

The Company

 

Positron Corporation is a medical technology company committed to advancing the PET imaging modality through the development, manufacturing, and commercialization of its state-of-the-art PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems. With a strong focus on cardiac PET-the gold standard in nuclear cardiology-Positron provides cutting-edge solutions that enhance diagnostic accuracy, improve patient outcomes, and drive cost-effective care for healthcare providers across North America.

 

Positron’s imaging portfolio includes a dedicated PET only and 3D PET-CT 64-Slice systems, both designed to expand access to advanced molecular imaging. Additionally, Positron is preparing to introduce its 4D PET-CT 64-Slice scanner, further strengthening its role in the evolution of nuclear cardiology while positioning the company for entry into the oncology imaging market. These innovations, supported by Positron’s comprehensive clinical and technical services, enable nuclear cardiologists and imaging specialists to fully leverage PET technology for superior diagnostic capabilities.

 

Through a strategic partnership with Shenyang Intelligent Nuclear Medical Technology Co. Ltd., a subsidiary of Neusoft Medical Systems, Positron holds exclusive North American distribution rights and FDA 510(k) clearance for the NeuSight PET-CT (3D) system. Additionally, Positron and Neusoft have co-developed the Affinity PET-CT (4D), which Positron will manufacture, distribute, and service. The company plans to amend its existing 510(k) clearance to include the Affinity PET-CT, ensuring regulatory compliance and market readiness upon FDA clearance.

 

Positron’s collaboration with Neusoft Medical Systems extends to the production of its Attrius PET system, a foundational technology for its PET-CT advancements. This joint effort has been instrumental in expanding Positron’s PET-CT offerings, setting the stage for rapid growth across multiple imaging disciplines. With an emphasis on accessibility, affordability, and technological excellence, Positron is well-positioned to meet the rising demand for PET-CT imaging in nuclear cardiology and oncology, delivering best-in-class solutions that optimize patient care and streamline practice efficiencies.

 

Positron’s Headquarters is in North Tonawanda, NY.

 

Critical Accounting Policies and Estimates

 

The discussion and analysis of our financial condition and results of operations is based upon our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions.

 

5

 

 

We define critical accounting policies as those that are reflective of significant judgments and uncertainties, and which may potentially result in materially different results under different assumptions and conditions. In applying these critical accounting policies, our management uses its judgment to determine the appropriate assumptions to be used in making certain estimates. These estimates are subject to an inherent degree of uncertainty. Our critical accounting policies include the following:

 

Financial Instruments with Characteristics of Both Liabilities and Equity

 

The Company evaluates equity or liability classification for freestanding financial instruments, including convertible preferred stock, warrants, and options, pursuant to the guidance under FASB ASC Topic 480, Distinguishing Liabilities from Equity (“ASC 480”). The Company classifies as liabilities all freestanding financial instruments that are (i) mandatorily redeemable, (ii) represent an obligation to repurchase the Company’s equity shares by transferring assets, or (iii) represent an unconditional obligation (or conditional obligation if the financial instrument is not an outstanding share) to issue a variable number of shares predominantly based on a fixed monetary amount, variations in something other than the fair value of the Company’s equity shares, or variations inversely related to changes in fair value of the Company’s equity shares.

 

If a freestanding financial instrument does not represent an outstanding equity share and does not meet liability classification under ASC 480, the Company then assesses whether the freestanding financial instrument is indexed to its own stock and meets equity classification pursuant to FASB ASC 815-40, Derivatives and Hedging (“ASC 815”). The Company further assesses whether the freestanding financial instruments should be classified as temporary equity. Freestanding financial instruments that are redeemable for cash or other assets at a fixed or determinable date, at the option of the holder, or upon the occurrence of an event are classified in temporary equity in accordance with FASB ASC 480. Otherwise, the freestanding financial instruments are classified in permanent equity.

 

Revenue Recognition

 

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. Revenue is recognized when or as control of promised goods or services is transferred to the customer in an amount that reflects the consideration the Company expects to receive in exchange for those goods or services. The Company applies the following five-step model:

 

(i) identify the contract with a customer;

 

(ii) identify the performance obligations in the contract;

 

(iii) determine the transaction price;

 

(iv) allocate the transaction price to the performance obligations in the contract; and

 

(v) recognize revenue when, or as, performance obligations are satisfied.

 

Nature of Services and Performance Obligations

 

The Company generates revenue primarily from clinical, technical, and maintenance service contracts that provide customers with ongoing product support and from sales of equipment. These contracts are generally one-year agreements that automatically renew for successive one-year periods unless terminated by either party with at least 90 days’ notice. The Company considers only the noncancelable initial term and any renewal periods for which the customer has a material right when determining the contract term and performance obligations.

 

Each maintenance contract represents a single distinct performance obligation. The various service elements - including priority response, 24/7 clinical and technical support, parts and labor, preventative maintenance, software upgrades, uptime guarantees, remote diagnostic capabilities, daily quality assurance inspections, and applications training - are highly integrated and interdependent. They are not separately identifiable from one another and are accounted for as a single stand-ready performance obligation that is satisfied continuously over the contract term.

 

6

 

 

Significant Judgments

 

In applying ASC 606, the Company makes the following significant judgments that affect the timing and amount of revenue recognized:

 

(i) the Company concluded that all services under each maintenance contract constitute a single performance obligation because they are highly interrelated and provide a combined integrated service to the customer;

 

(ii) for maintenance contracts, the Company uses a time-based, straight-line output method to measure progress, which it has determined faithfully depicts the Company’s performance as the customer simultaneously receives and consumes the benefits of the services; and

 

(iii) for equipment sales, the Company applies judgment in assessing when control transfers to the customer.

 

No changes to these judgments have occurred during the periods presented.

 

Transaction Price and Allocation

 

The transaction price is the fixed fee stated in each contract. The Company generally does not offer refunds, rebates, discounts, or variable pricing incentives. Maintenance contract fees are typically billed monthly in advance with payment due within 30 days. As permitted by the practical expedient in ASC 606-10-32-18, the Company does not adjust the transaction price for the effects of a significant financing component when the period between transfer of control of the good or service and customer payment is one year or less. Because each contract contains a single performance obligation, the entire transaction price is allocated to that obligation.

 

Revenue Recognition - Timing

 

The Company recognizes revenue either over time or at a point in time depending on the nature of the performance obligation.

 

Maintenance contract revenue is recognized over time as the customer simultaneously receives and consumes the benefits of the services as they are provided. Revenue is recognized ratably on a straight-line basis over the contract term. Amounts received in advance of services being provided are recorded as deferred revenue and recognized as revenue as the related performance obligations are satisfied.

 

Equipment sale revenue is recognized at a point in time when control of the equipment transfers to the customer, which occurs upon physical delivery and acceptance of the equipment and where collection is probable. In the three and nine months ended September 30, 2026 and 2025, no equipment sale revenue had been recognized, as the conditions for transfer of control had not yet been met.

 

Principal vs. Agent Considerations

 

The Company has determined that it acts as a principal in all revenue transactions. The Company controls the services prior to transfer to the customer, is responsible for fulfilling all contractual obligations including uptime guarantees, bears the risk of performance, and has discretion in establishing contract pricing. Accordingly, revenue is recognized on a gross basis.

 

Contract Balances and Remaining Performance Obligations

 

The Company’s contract liabilities consist of deferred revenue related to maintenance contracts billed in advance and customer deposits on pending equipment sales. These amounts are presented as deferred revenue on the accompanying balance sheets. There were no contract assets as of September 30, 2026 or December 31, 2025.

 

The Company has elected the practical expedient under ASC 606-10-50-14 not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for contracts with an original expected duration of one year or less.

 

All revenue recognized in both periods was derived from maintenance service contracts. No equipment sale revenue has been recognized in either period, as transfer of control of the equipment to the customer had not yet occurred as of each respective balance sheet date.

 

Deferred Revenue (Contract Liabilities)

 

Deferred revenue represents consideration received from customers prior to the satisfaction of the related performance obligation.

 

Maintenance contract amounts represent consideration received from customers prior to the applicable service period and are recognized as revenue ratably as performance obligations are satisfied over the service term.

 

Inventory Net Realizable Value

 

Inventory is stated at the lower of cost or net realizable value. At September 30, 2026, inventory of $680,000 consisted of the Company’s sole imaging system, measured at its estimated selling price under an executed sales agreement, less estimated costs to complete and sell. Additional equipment costs of $238,352 incurred during the nine months ended September 30, 2026 to ready the unit for sale were written down to net realizable value.

 

Fair Value of Warrants

 

The Company estimates the fair value of warrants using the Black-Scholes-Merton option pricing model. Expected volatility is the input with the most significant effect on fair value. A ten (10) percentage point decrease in expected volatility would have reduced the fair value of the 300,000 line of credit warrants by approximately $18,975 and the debt discount allocated to the 380,000 warrants issued with Notes #5 and #6 by approximately $17,323.

 

7

 

 

Related Parties

 

The Company defines related parties in accordance with ASC 850, “Related Party Disclosures,” and SEC Regulation S-X, Rule 4-08(k). Related parties include entities and individuals that, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company.

 

Related parties include, but are not limited to:

 

  ● Principal owners of the Company.
     
  ● Members of management (including directors, executive officers, and key employees).
     
  ● Immediate family members of principal owners and members of management.
     
  ● Entities affiliated with principal owners or management through direct or indirect ownership.
     
  ● Entities with which the Company has significant transactions, where one party has the ability to exercise control or significant influence over the management or operating policies of the other.

 

A party is considered related if it has the ability to control or significantly influence the management or operating policies of the Company in a manner that could prevent either party from fully pursuing its own separate economic interests.

 

The Company discloses all material related party transactions, including:

 

  ● The nature of the relationship between the parties.
     
  ● A description of the transaction(s), including terms and amounts involved.
     
  ● Any amounts due to or from related parties as of the reporting date.
     
  ● Any other elements necessary for a clear understanding of the transactions’ effects on the financial statements.

 

Disclosures are made in accordance with ASC 850-10-50-1 through 50-6 and SEC Regulation S-X, Rule 4-08(k), which requires registrants to disclose material related party transactions and their effects on the financial position and results of operations.

 

8

 

 

Results of Operations

 

Results of operations for the three months ended September 30, 2026 and 2025.

 

    For the Three Months Ended September 30,     Period Change  
    2026     2025     $ Change     % Change  
Sales   $ 102,667     $ 111,000     $ (8,333 )     (7.5 %)
Cost of sales     492,108       367,161       124,947       34.0 %
Gross loss     (389,441 )     (256,161 )     (133,280 )     (52.0 %)
General and administrative expenses     527,947       749,992       (222,045 )     (29.6 %)
Loss from operations     (917,388 )     (1,006,153 )     88,765       8.8 %
Other income (expense)                                
Interest expense - related parties     (57,069 )     (30,247 )     (26,822 )     (88.7 %)
Interest and other income     2,475       7,478       (5,003 )     (66.9 %)
Loss on lease termination             (15,018 )     15,018       100.0 %
Total other income (expense) - net     (54,594 )     (37,787 )     (16,807 )     (44.5 %)
Net loss   $ (971,982 )   $ (1,043,940 )   $ 71,958       6.9 %

  

Revenues - Revenues for the three months ended September 30, 2026, were $102,667 as compared to $111,000 for the three months ended September 30, 2025. The slight decrease of $8,333 in revenue was based on a customer opting for time and materials service agreements vs fixed annual services agreement.

 

Costs of Sales - Costs of sales for the three months ended September 30, 2026, were $492,108, as compared to $367,161 for the three months ended September 30, 2025, due to additional personnel and expenses related to product testing. Costs of sales for the three months ended September 30, 2026 included $190,626 of additional equipment costs to ready a unit for sale. No inventory write-down was recorded during the three months ended September 30, 2026.

 

General and Administrative Expenses - The Company’s operating expenses were $527,947 for the three months ended September 30, 2026, compared to $749,992 for the three months ended September 30, 2025. The decrease of $222,045 was due to lower spending on sales and marketing, hardware/software upgrades to existing systems, business development, consultants and corporate operations.

 

Other Expenses - During the three months ended September 30, 2026 and 2025, the Company recorded other expenses - net of $54,594 and $37,787, respectively. Other expenses include interest expense, including amortization of deferred financing costs, and in 2025, a loss on lease termination of $15,018. Other income includes interest income and other income.

 

Interest expense - related parties was $57,069 and $30,247 for the three months ended September 30, 2026 and 2025, respectively. Interest expense for the three months ended September 30, 2026 included $35,014 of amortization of deferred financing costs related to the line of credit - related party entered into on August 13, 2026.

 

During the three months ended September 30, 2026, and 2025, the Company recorded interest and other income of $2,475 and $7,478, respectively. Interest and other income for the three months ended September 30, 2026 included other income of $2,057.

 

Net Loss - For the three months ended September 30, 2026, the Company had a net loss of $971,982, or ($0.03) per share, compared to a net loss of $1,043,940, or ($0.03) per share, for the three months ended September 30, 2025.

 

Results of operations for the nine months ended September 30, 2026 and 2025.

 

9

 

 

    For the Nine Months Ended September 30,     Period Change  
    2026     2025     $ Change     % Change  
Sales   $ 325,489     $ 350,452     $ (24,963 )     (7.1 %)
Cost of sales     1,506,659       1,146,626       360,033       31.4 %
Gross loss     (1,181,170 )     (796,174 )     (384,996 )     (48.4 %)
General and administrative expenses     1,905,089       2,803,258       (898,169 )     (32.0 %)
Loss from operations     (3,086,259 )     (3,599,432 )     513,173       14.3 %
Other income (expense)                                
Interest expense - related parties     (102,233 )     (95,091 )     (7,142 )     (7.5 %)
Interest and other income     17,341       7,478       9,863       131.9 %
Loss on lease termination             (15,018 )     15,018       100.0 %
Total other income (expense) - net     (84,892 )     (102,631 )     17,739       17.3 %
Net loss   $ (3,171,151 )   $ (3,702,063 )   $ 530,912       14.3 %

 

Revenues - Revenues for the nine months ended September 30, 2026, were $325,489 as compared to $350,452 for the nine months ended September 30, 2025. The slight decrease of $24,963 in revenue was based on a customer opting for time and materials service agreements vs fixed annual services agreement.

 

Costs of Sales - Costs of sales for the nine months ended September 30, 2026, were $1,506,659, including payments of $238,352 in 2026, for additional equipment to ready a unit for sale, resulting in a corresponding inventory write-down of $238,352, as compared to $1,146,626 for the nine months ended September 30, 2025, due to additional personnel and expenses related to product testing.

 

General and Administrative Expenses - The Company’s operating expenses were $1,905,089 for the nine months ended September 30, 2026, compared to $2,803,258 for the nine months ended September 30, 2025. The decrease of $898,169 was primarily due to the payment of an NRE fee of $490,000 during the nine months ended September 30, 2025, and lower spending on sales and marketing, hardware/software upgrades to existing systems, business development, consultants and corporate operations. During the nine months ended September 30, 2026, the Company recorded $94,500 in stock based compensation for digital marketing services.

 

Other Expenses - During the nine months ended September 30, 2026 and 2025, the Company recorded other expenses - net of $84,892 and $102,631, respectively. Other expenses include interest expense, including amortization of deferred financing costs, and in 2025, a loss on lease termination of $15,018. Other income includes interest income and other income.

 

Interest expense - related parties was $102,233 and $95,091 for the nine months ended September 30, 2026 and 2025, respectively. Interest expense for the nine months ended September 30, 2026 included $35,014 of amortization of deferred financing costs related to the line of credit - related party.

 

During the nine months ended September 30, 2026, and 2025, the Company recorded interest and other income of $17,341 and $7,478, respectively. Interest and other income for the nine months ended September 30, 2026 included other income of $2,057.

 

Net Loss - For the nine months ended September 30, 2026, the Company had a net loss of $3,171,151, or ($0.10) per share, compared to a net loss of $3,702,063, or ($0.12) per share, for the nine months ended September 30, 2025.

 

Liquidity and Capital Resources

 

Since inception, the Company has sustained substantial losses. Revenues have also fluctuated significantly from year to year. The Company had an accumulated deficit of $148,108,230 at September 30, 2026. The Company will need to continue to increase sales and/or rental of systems and services to achieve profitability in the future.

 

10

 

 

The Company’s ability to achieve its objectives is dependent on its ability to sustain and enhance its revenue stream and/or to raise capital until such time as the Company achieves profitability. To date, management has been successful in raising capital as needed for the continued operations of the Company. There is no guarantee that management will be able to continue to raise capital if needed in the future, and if able to raise these funds, obtaining this capital may not be on favorable terms.

 

The Company has cash on hand of $1,925,653 at September 30, 2026. The Company does not expect to generate sufficient revenues and positive cash flow from operations sufficiently to meet its current obligations, including a working capital deficiency of $1,200,539. At September 30, 2026, the Company had $2,000,000 available under its line of credit - related party, under which no advances had been drawn, subject to a maximum of $500,000 per calendar quarter and fourteen (14) days written notice per advance. However, the Company may seek to raise debt or equity-based capital at favorable terms, though such terms are not certain.

 

    Balance at     Period Change  
    September 30,
2026
    December 31,
2025
    $ Change     % Change  
Cash and cash equivalents   $ 1,925,653     $ 2,520,466     $ (594,813 )     (23.6 %)
Total current assets     2,879,008       3,339,186       (460,178 )     (13.8 %)
Total current liabilities     4,079,547       2,402,141       1,677,406       69.8 %
Working capital (deficiency)   $ (1,200,539 )   $ 937,045     $ (2,137,584 )     (228.1 %)

  

These factors create substantial doubt about the Company’s ability to continue as a going concern within the twelve-month period subsequent to the date that these financial statements are issued. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Accordingly, the financial statements have been prepared on the basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.

 

Management’s strategic plans include the following:

 

  ● Execute business operations more fully during the current year.
     
  ● Expand its reach within nuclear cardiology with the launch of our PET-CT system which provides greater features and functions now available to nuclear cardiologists and their diagnostic capabilities.
     
  ● Enter the vast oncology market with its new PET-CT system with a faster, smaller, more economical solution for practices, hospitals, and patients.
     
  ● Explore and execute prospective strategic and partnership opportunities; and
     
  ● Pursue to “Up-List” to a more prominent publicly reporting exchange.

 

At September 30, 2026, the Company had current assets of $2,879,008 and total assets of $3,656,719 compared to December 31, 2025, when current assets were $3,339,186 and total assets were $3,999,649. The decrease in total assets is attributable primarily to a reduction in cash to meet working capital needs, depreciation of property and equipment and usage of prepaid assets expensed in the current period ended September 30, 2026, partially offset by deferred financing costs of $385,163 related to the line of credit - related party.

 

Total liabilities at September 30, 2026, were $4,206,942 compared to $2,555,827 at December 31, 2025. The increase is attributable primarily to notes payable - related parties, net of debt discount, issued September 30, 2026, and an increase in accounts payable and accrued expenses. Total liabilities were largely comprised of accounts payable and accrued expenses with 3rd parties and related parties, deferred revenues, notes and other debt as well as its operating lease.

 

11

 

 

   For the Nine Months Ended September 30,   Period Change 
   2026   2025   $ Change   % Change 
Operating activities  $(2,419,813)  $(3,363,257)  $943,444    28.1%
Investing activities        (76,524)   76,524    100.0%
Financing activities   1,825,000    5,250,000    (3,425,000)   (65.2%)
Net change in cash  $(594,813)  $1,810,219   $(2,405,032)   (132.9%)

 

Net cash used in operating activities during the nine months ended September 30, 2026, was $2,419,813 compared to $3,363,257 used in operating activities during the nine months ended September 30, 2025.

 

Net cash used in investing activities during the nine months ended September 30, 2026, was $0 compared to $76,524 used in investing activities during the nine months ended September 30, 2025.

 

Net cash provided by financing activities was $1,825,000 and $5,250,000 for the nine months ended September 30, 2026, and 2025, respectively. During the nine months ended September 30, 2026, the Company had cash inflows of $1,900,000 from notes payable - related parties and $250,000 from the exercise of warrants by a related party, offset by repayments on notes payable - related party of $325,000. During the nine months ended September 30, 2025, the Company had cash inflows of $8,000,000 from the sale of common stock and $100,000 from a note payable - related party, offset by cash paid to repurchase and retire common stock of $2,500,000 and repayments on notes payable - related party of $350,000.

 

Subsequent to September 30, 2026, the Company received $100,000 under an unsecured promissory note, and a related party delivered notice to exercise 300,000 warrants for an aggregate exercise price of $450,000, payment for which had not been received as of the date of this report.

 

Off-Balance Sheet Arrangements

 

We have not entered into any transactions with unconsolidated entities whereby we have financial guarantees, subordinated retained interests, derivative instruments or other contingent arrangements that expose us to material continuing risks, contingent liabilities, or any other obligations under a variable interest in an unconsolidated entity that provides us with financing, liquidity, market risk or credit risk support.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

As a “smaller reporting company”, the Company is not required to provide the information required by this item.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

12

 

 

An evaluation was conducted under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2026. Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective as of such date to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. Such officer also confirmed that there was no change in our internal control over financial reporting during the three months ended September 30, 2026 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

Our disclosure controls and procedures were not effective due to the material weaknesses in our internal control over financial reporting described in our Annual Report on Form 10-K for the year ended December 31, 2025, consisting of:

 

  (i) inadequate segregation of duties consistent with control objectives; and

 

  (ii) lack of multiple levels of supervision and review.

 

Changes in Internal Control Over Financial Reporting

 

There have been no changes in our internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under Exchange Act) that occurred during the quarter ended September 30, 2026, that have materially or are reasonably likely to materially affect, our internal controls over financial reporting.

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings

 

We are not aware of any legal proceedings to which we are a party or of which our property is the subject. None of our directors, officers, affiliates, any owner of record or beneficially of more than 5% of our voting securities, or any associate of any such director, officer, affiliate or security holder are (i) a party adverse to us in any legal proceedings, or (ii) have a material interest adverse to us in any legal proceedings. We are not aware of any other legal proceedings that have been threatened against us.

 

Item 1A. Risk Factors

 

As a “smaller reporting company”, the Company is not required to provide the information required by this item.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

During the three months ended September 30, 2026, the Company issued the following securities that were not registered under the Securities Act of 1933, as amended (the “Securities Act”):

 

  ● On August 13, 2026, warrants to purchase 300,000 shares of common stock at an exercise price of $1.50/share, expiring December 31, 2030, issued to a significant stockholder as consideration for a $2,000,000 line of credit commitment.

 

  ● On September 2, 2026, 250,000 shares of common stock issued to a significant stockholder upon the exercise of warrants at an exercise price of $1/share, for cash proceeds of $250,000.

 

  ● On September 30, 2026, warrants to purchase 380,000 shares of common stock at an exercise price of $2/share, expiring December 31, 2030, issued to a significant stockholder (300,000 warrants) and to an entity affiliated with a member of the Board of Directors (80,000 warrants) in connection with promissory notes in the aggregate principal amount of $1,900,000.

 

The securities were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act, as transactions by an issuer not involving a public offering. Each recipient is a related party of the Company with access to information about the Company. No underwriter or placement agent was involved and no commissions were paid. The proceeds from the warrant exercise and the promissory notes were used for working capital and general corporate purposes.

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

(a) None.

 

(b) Corporate Governance

 

During the period covered by this Quarterly Report on Form 10-Q, there were no changes to the procedures by which security holders may recommend nominees to the Company’s Board of Directors.

 

(c) Insider Trading Arrangements and Policies

 

During the period covered by this Quarterly Report on Form 10-Q, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K. 

 

13

 

 

Item 6. Exhibits

 

Exhibit    
Number   Description
10.1*   Line of Credit Agreement dated August 13, 2026 between Positron Corporation and George Ortiz
10.2*   Warrant to Purchase Common Stock issued August 13, 2026 to George Ortiz
10.3*   Promissory Note dated September 30, 2026 in the principal amount of $1,500,000 issued to George Ortiz
10.4*   Promissory Note dated September 30, 2026 in the principal amount of $400,000 issued to TISU Investments LTD
10.5*   Form of Warrant to Purchase Common Stock issued September 30, 2026
31.1*   Certification of Principal Executive Officer and Principal Financial Officer, pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934
32.1*   Certification of Principal Executive Officer and Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101**   Interactive Data File
101.INS   Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCH   Inline XBRL Taxonomy Extension Schema Document
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

 

* Filed herewith.
** Furnished herewith.

 

14

 

 

SIGNATURES

 

Pursuant to the requirements of Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    POSITRON CORPORATION
     
Dated: November 13, 2026   /s/ Adel Abdullah
    Adel Abdullah
    President and Chairman
    (Principal Executive and Financial Officer)

 

15

Keep reading